Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

ThreeBond

ThreeBond International Inc.

Premium
Information Technology

ThreeBond International, Inc. is the North and Central American arm of Japan's ThreeBond Group, one of the founding names in formed-in-place liquid gaskets. It develops, manufactures, coats and sells industrial sealants, adhesives, coatings, cleaners, dispensing equipment and pre-applied threadlocking coatings for fasteners. Its customers are mainly automotive OEMs and their tier suppliers, with smaller but strategically important positions in EV and fuel-cell assembly, consumer electronics, small engines, motorsports, nail care and medical devices. The company runs from a West Chester, Ohio headquarters with a fastener pre-coating plant in Moraine, Ohio, and branch offices in Michigan and Silicon Valley. It coordinates the group's Mexican affiliate and Canadian sales. Its competitive identity rests on the parent's catalogue of about 1,600 products, made-to-order formulation, and long-standing approval positions with Japanese transplant automakers. Its exposure is concentrated in North American light-vehicle production and in the transition from internal-combustion to electrified powertrains. --- ### Company's own description (paraphrased) The North American website describes the business this way: - ThreeBond International is a global technology leader in industrial adhesives, sealants and coatings. - Its Cincinnati-area headquarters manages sales and manufacturing across the United States, Mexico and Canada. - It differentiates itself through close customer partnership and service. The parent group frames its mission around founder Osamu Ukumori's goal of preventing the leakage of precious energy and resources. It describes its product range as more than 1,600 types serving automotive, transportation equipment, public works and industrial materials, construction, electrical/electronics, and high-technology fields. (Sources: threebond.com homepage and /about; threebond.co.jp/en/company/about, accessed Oct 2026.) The group directory lists five functions for the U.S. entity: 1. Overall management control. 2. Development of products and coating equipment. 3. Industrial-materials sales, drawing on about 1,600 products. 4. Automotive aftermarket supplies for car dealers. 5. Production of adhesives and sealants. The Moraine site is classed as "Processing", which the group defines as applying resin to bolts. (threebond.co.jp overseas-office pages.) ### Business model and revenue model | Revenue stream | Description | Est. mix | |---|---|---| | Product sales: OEM industrial | Sealants, adhesives and coatings sold direct to automotive, electronics and industrial manufacturers, typically under part-number approvals and specifications | n/d (judged the dominant stream) | | Product sales: aftermarket | Branded tubes and cans (RTV silicones, threadlockers, cleaners) sold to dealers and service channels | n/d | | Processing services | Pre-application of threadlocking and sealing coatings to customer fasteners at the Moraine plant ("Pre-Coated Fasteners (MEC)") | n/d | | Equipment | "Engineered Dispensing Solutions": dispensing and coating equipment supporting adhesive use | n/d | | Custom development | Made-to-order formulations, in some cases priced into product rather than charged as fees | n/d | | Subscription / licensing | None disclosed | 0 (none disclosed) | ### Value-chain position The group sits in the middle of the specialty-chemicals chain. It buys base resins and monomers (silicones, acrylics, epoxies, cyanoacrylates) and formulates proprietary compounds. Some of this is done in Japan and imported, and some is done locally in Ohio. The products are sold into Tier-1/Tier-2 component makers and OEM assembly lines. The group's upstream dependence is visible in its 1 June 2026 notice about the impact of Mitsubishi Chemical discontinuing some epoxy-resin grades (threebond.co.jp news 2026). U.S. customs records show inbound shipments from Three Bond Co., Ltd. (Hong Kong), Alucon Public Co., Ltd. (Thailand) and Caretell Chemical Co., Ltd. The top HS chapters are 35 (glues), 39 (plastics) and 76 (aluminium articles), which suggests imports of finished adhesives and of aluminium packaging such as tubes. (Panjiva: 112 U.S. shipments since 2007; latest dated Feb 2025.) ### Customer types and end-markets The end-markets listed on threebond.com are: - Automotive Manufacturing - EV & Fuel Cell Manufacturing - Automotive Aftermarket - Motorsports Manufacturing & Aftermarket - Small Engine Manufacturing - Consumer Electronics - Nail Care Products - Custom Product Development - Medical Grade Products At group level, the four business markets are Automotive, Electronics, Public Industrial Material and Auto Aftermarket (threebond.co.jp navigation). The group reports trading with more than 20,000 companies worldwide (onecareer.jp, 2026). ### Independent characterization ThreeBond International is best understood as a captive regional distribution, application-engineering and light-manufacturing platform for a Japanese formulator. It is not a stand-alone chemicals company. Its economics are most likely driven by: 1. Specification wins at Japanese-affiliated automakers and suppliers in the U.S. Midwest, South and Mexico. 2. Per-vehicle content of formed-in-place gaskets and threadlockers. 3. Processing volume at Moraine. The website emphasis on EV/fuel-cell sealing, thermal-dissipation adhesives and medical-grade products shows a deliberate effort to diversify away from engine-gasket content. That content is structurally exposed to battery-electric vehicle adoption.

RevenueN/A
Employees3,376
Market CapN/A
Founded1955
OH, US

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Thor

Thor Group Limited

Premium
Information Technology

THOR is a privately owned, UK-headquartered speciality chemicals group with nearly seven decades of history. It is one of the world's established independent producers of industrial biocides. Its Acticide® franchise preserves water-based paints, coatings, adhesives, polymer emulsions, detergents, fuels and many other products against microbial spoilage. The group is vertically integrated into its own active substances, such as isothiazolinones, formaldehyde donors, IPBC and quaternary ammonium compounds. Around biocides it has built three adjacent businesses: - Disinfection - Personal Care, under the Microcare® preservatives brand - Performance Chemicals, including Aflammit® flame retardants and the newer Amaval™ multifunctional additives With €642m of FY2025 turnover, a 19.2% EBITDA margin and €150m of cash, THOR differs from listed peers in three ways. It is debt-free, it pays out most of its earnings as dividends, and it runs a decentralised operating model across 14 operating units. Its main strategic exposures are EU regulation under the BPR and REACH, decorative-coatings demand, and raw-material-driven price competition. --- **Company's own description.** In its FY2025 report, the group describes itself as focused on developing, manufacturing and supplying speciality chemical solutions to a diversified global customer base. It operates through a network of manufacturing sites, distribution sites and technical support centres, supported by central governance, finance, digital, procurement and R&D functions. The holding company's stated role is to allocate capital, provide governance and leadership, and support strategy execution across its subsidiaries. The group's principal activity is "the manufacture and distribution of speciality chemicals" [TATO-25, Strategic and Directors' Reports]. The group's marketing describes THOR ingredients as everyday but invisible. They preserve washing-up liquids and detergents, protect furniture and clothing in the event of fire, and enhance moisturisers and shampoos [WEB / LinkedIn company profile]. **Business model.** THOR is a business-to-business ingredients manufacturer. It sells active substances and formulated additives, which customers dose at low concentrations into their own products. FY2025 business units [TATO-25]: **Revenue model.** Revenue comes almost entirely from product sales: manufactured goods recognised on despatch. A small "rendering of services" component is associated with product sales [TATO-25, note 1.5]. There are no subscription or licensing revenues of any disclosed significance. Technical service and microbiological testing are supplied through Technical Service Centres. These centres support sales but are not separately monetised in disclosed figures. Pricing is transactional and competitive. In FY2025 the group reported "continued downwards pressure on market pricing" amid falling raw-material prices, while volumes grew 4.1% [TATO-25]. **Value-chain position.** THOR sits in the middle of the chemicals value chain. It buys commodity and intermediate raw materials; the largest Scope 3 category is purchased chemicals and raw materials [TATO-25]. It synthesises its own biocidal actives at major sites; the company states isothiazolinones are available from "three major Thor sites" [WEB]. It then formulates finished additive blends. Customers are formulators such as paint makers, adhesive producers, detergent and cosmetics brands, textile finishers and plastics compounders. Vertical integration into actives is a structural differentiator. In 2025 the group says added capacity reduced its "reliance on third party sourcing for key strategic actives" [TATO-25]. **Customer types and end-markets** [WEB product pages; TATO-25; CB Insights]: - Paints, plasters and decorative coatings. This is the largest single reference market cited in the annual report. - Polymer emulsions, adhesives and sealants. - Construction and concrete; minerals and slurries. - Household products, detergents and wet wipes. - Metal-working fluids, fuels, water treatment, and pulp and paper. - Plastics and wood-plastic composites (WPC); textiles and leather. - Cosmetics, toiletries and personal care. - Institutional, industrial and healthcare disinfection, including dialysis-centre applications featured in company news [WEB]. - Flame-retardant applications in textiles, furniture and plastics. **Independent characterisation.** THOR is a mid-sized, family-heritage, regulation-intensive niche player. Its economic moat comes from three things: 1. The cost and duration of maintaining biocide active-substance registrations (EU BPR, UK BPR, US EPA, Mexico COFEPRIS). 2. Captive active-substance manufacturing. 3. Technical-service intimacy with formulators. Its financial profile is that of a mature, cash-generative industrial business. Revenue has been flat to slightly down since 2022 (FY2022 €688.9m to FY2025 €641.9m). Margins recovered after a 2023 destocking trough, there is no financial debt, and payout ratios run at 80–95% of net profit. Growth is being pursued organically through capacity (the €18m Speyer Building 4) and adjacencies (Personal Care, Disinfection, Performance Chemicals), rather than by acquisition.

Revenue$0.7B
Employees500
Market CapN/A
Founded1959
Bramling, New Zealand
Thirumalai

Thirumalai Chemicals Limited

Premium
Information Technology

Thirumalai Chemicals is a five-decade-old Indian producer of phthalic anhydride (PAN) and its derivatives, and of maleic-anhydride-based food acids (malic and fumaric acid). It is India's second-largest PAN producer behind I G Petrochemicals, describes itself as among the world's top three PAN manufacturers, the largest fumaric-acid producer in India, and the largest maleic anhydride (MAN) producer in Southeast Asia through its Malaysian subsidiary. Historically a cash-generative, near-debt-free commodity chemicals franchise (FY2022 consolidated PAT of INR 281 Cr), TCL has since FY2023 undertaken a transformational, largely debt-funded investment cycle: a large PAN/fumaric expansion at Dahej, Gujarat, and a greenfield MAN and food-acids complex in New Martinsville, West Virginia, now budgeted at USD 340 million. The combination of compressed PAN–orthoxylene spreads, idle Malaysian capacity and US project cost overruns has produced three consecutive loss-making years, a sharply higher leverage profile, covenant waivers and five ICRA downgrades since May 2025. The equity story is now a binary bet on US commissioning (targeted December 2026) and balance-sheet repair. --- ### What the company does Thirumalai Chemicals manufactures and sells organic chemicals in two broadly related value chains: 1. **Phthalic anhydride chain (bulk/commodity):** PAN is produced by catalytic oxidation of ortho-xylene (OX) at Ranipet (Tamil Nadu) and at Dahej (Gujarat, via subsidiary TCL Intermediates Pvt Ltd). PAN is sold to plasticiser makers (PVC cables, flooring, films), unsaturated polyester resin (UPR) producers (fibre-reinforced plastics), alkyd-resin/paint manufacturers, and copper phthalocyanine (CPC) pigment makers. Downstream PAN derivatives include diethyl phthalate (DEP), phthalate esters and phthalimide (PID). 2. **Maleic anhydride and food-acid chain (specialty):** MAN is produced from butane (Malaysia; US under commissioning). MAN is the feedstock for malic acid and fumaric acid, which TCL sells in food, beverage, confectionery, bakery, animal feed, pharmaceutical (fumaric acid as API), personal-care and industrial (UPR, alkyd resin, inks) applications. TCL produces both food-grade and pharma-grade malic acid at Ranipet. Per the FY26 Annual Report, revenue mix is approximately 84% bulk commodity and 16% specialty chemicals. A secondary capability is TCL Technology & Engineering (TCL-TE), an in-house division that designs, fabricates and supplies "ready-to-start-up" modular process plants and skids. TCL-TE built the modules for the West Virginia project. TCL also historically generated wind power in Tamil Nadu; four windmills are being sold (Aug 2026). ### Company's own description (paraphrased from FY2025-26 Annual Report) The company presents itself as a globally integrated specialty chemicals group that evolved from a single PAN plant at Ranipet into a multi-product, multi-geography enterprise operating in India, Malaysia and the United States, with more than 350 customers across roughly 60 countries. It emphasises that its products go into everyday goods — paints, cable plasticisers, beverage acidulants and pharmaceutical ingredients — and that a key differentiator is the ability to span both industrial-grade and food-grade production within an integrated manufacturing model. Management highlights energy self-sufficiency (over 90% of PAN-operations energy from recovered process heat), zero liquid discharge at Ranipet, and a long-term, discipline-first culture rather than aggressive diversification. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | ~100% product sales (manufactured chemicals). No subscription or licensing revenue disclosed. Engineering (TCL-TE) is primarily captive. Wind-power income historically immaterial (power segment de-recognised as reportable in 2018) | | Pricing | Spot and contract pricing; ICRA notes medium- to long-term contracts with many customers, but realisations track regional PAN supply–demand and OX costs | | Key input | Ortho-xylene, sourced under a long-standing relationship with Reliance Industries on an "assured offtake model" (ICRA); butane for MAN (Malaysia, US); MAN for food acids; ethanol for DEP | | Value-chain position | Mid-stream intermediate producer: buys petrochemical feedstock, sells intermediates to formulators/converters. Limited product differentiation in PAN; more differentiation (food/pharma grades, certifications) in food acids | | Customer types | Plasticiser and resin manufacturers, paint and pigment makers, food and beverage processors, pharmaceutical companies, animal-feed producers, personal-care/fragrance formulators (DEP) | | End-markets | Construction/infrastructure, automotive, paints and coatings, food and beverage, pharmaceuticals, personal care (ICRA, Jun 2026) | | Geographic sales | FY26: ~90% India, ~10% exports (Annual Report); export mix Europe 43%, North America 25%, Asia 19%, Africa 13% | ### Independent characterisation TCL is best understood as a spread business with an embedded growth option. The core Indian PAN franchise earns the PAN–OX spread, which is set largely by Chinese and Korean supply and by anti-dumping protection in India; when spreads are healthy (FY2022) the business generates 20%+ EBITDA margins and strong free cash flow, and when spreads compress (FY2024–FY2026) margins collapse to low single digits or negative. The food-acids business is structurally more attractive — higher value, sticky regulated customers — but it is small relative to PAN and its MAN feedstock economics have been undermined by Chinese oversupply, which has rendered the Malaysian MAN plant largely non-operational. The West Virginia project is a strategic attempt to relocate the higher-value MAN/food-acids chain into a tariff-protected, under-supplied North American market with advantaged shale-gas butane. The problem is that it has been financed predominantly with debt at the same time the core PAN cash engine stalled, producing a classic capex-cycle squeeze.

Revenue$0.2B
Employees477
Market CapN/A
Founded1944
Mumbai, India
Thermax

Thermax Limited

Premium
Information Technology

Thermax is India's leading independent provider of industrial energy and environment solutions, built over six decades around a single proposition: helping industrial customers convert energy and resource costs into profit while reducing environmental impact. Its portfolio spans process heating (boilers, thermic fluid heaters, waste-heat recovery), absorption cooling and heat pumps, utility and industrial power-plant boilers (via wholly owned TBWES), air pollution control (ESPs, FGD, bag filters), water and wastewater treatment including high-purity and zero-liquid-discharge systems, ion-exchange resins and specialty/construction chemicals, and a growing "green solutions" platform covering build-own-operate biomass steam, open-access renewable power, bio-CNG and green hydrogen. With FY2026 consolidated revenue of INR 10,694 crore (roughly USD 1.2 billion), a record INR 13,604 crore order backlog at March 2026, and 29% of sales now international, Thermax positions itself as a "trusted partner in energy transition" — a bridge between energy security and energy sustainability for Indian and emerging-market industry, with data-centre power and cooling as its newest growth vector. --- ### What the company does Thermax designs, engineers, manufactures, installs, operates and services equipment and systems that generate, recover and conserve thermal energy, generate captive and utility power, and clean air and water in industrial settings. It also manufactures chemicals that are consumed in those processes (ion-exchange resins, water-treatment and oilfield chemicals) and adjacent construction chemicals. Customers are overwhelmingly business-to-business: process industries (chemicals, pharmaceuticals, food and beverage, paper, textiles, steel, cement, metals and mining, refining and petrochemicals, sugar/distilleries), power utilities and independent power producers, infrastructure and urban bodies, and — increasingly — data-centre developers. ### The company's own description (latest annual report, paraphrased) In its Annual Report 2025-26 and recent press releases, Thermax describes itself as a leading company in the energy and environment space and a trusted partner in energy transition, with a portfolio covering clean air, clean energy, clean water and chemical solutions. It emphasises that its long-standing industry relationships across sectors have built capability in audit, consulting, execution and maintenance, supported by digital solutions, providing a unified energy-management experience. Its stated vision is to be a globally respected high-performance organisation offering sustainable solutions in energy and the environment, and its corporate line is "Conserving Resources, Preserving the Future." ### Business model and revenue model | Revenue model component | Description | Where it sits | Indicative weight | |---|---|---|---| | Engineered products (standard and configured) | Packaged boilers, thermic fluid heaters, absorption chillers/heat pumps, steam traps and accessories, air pollution control equipment, packaged water plants | Industrial Products | Largest contributor (~48% of FY2026 gross segment revenue) | | Projects / EPC and large equipment | Utility and industrial boilers (subcritical, supercritical, ultra-supercritical), captive power plants, FGD systems, large water/wastewater and ZLD plants, bio-CNG turnkey plants | Industrial Infra (and parts of Industrial Products and Green Solutions) | ~41% of FY2026 gross segment revenue | | Services and lifecycle | O&M at 383 project sites, spares, retrofits, upgrades, Thermax EDGE Live IIoT digital monitoring, Thermax Serve | Across segments | Not separately disclosed | | Build-own-operate (BOO) / energy-as-a-service | Long-term utility supply contracts (steam, heat, power) under BOO by TOESL; open-access solar, wind and hybrid power by First Energy (FEPL); bio-CNG sale | Green Solutions | ~7% of FY2026 gross segment revenue | | Consumables / chemicals | Ion-exchange resins, water-treatment chemicals, oilfield chemicals, construction chemicals, polymers | Chemical | ~7% of FY2026 gross segment revenue | | Licensing | Thermax is a licensee (Ceres SOEC, HydrogenPro alkaline electrolysers), not a licensor of material scale | n/a | Not material | Thermax runs a hybrid engineered-products, projects and annuity model: The product vs. service vs. subscription split is not publicly disclosed at group level. The BOO and open-access renewable businesses are effectively long-tenor contracted annuity revenue; TOESL changed its order-book methodology in Q1 FY2027 to a rolling 12-month forecast (adding INR 139 crore to reported backlog with no change to revenue recognition). ### Value-chain position Thermax sits in the mid-to-upper value chain: it owns core thermal and process technology (combustion design, heat-transfer engineering, absorption cycle design, resin chemistry), manufactures pressure parts and critical equipment in-house across 16 plants, and integrates third-party components (turbines, motors, instrumentation, membranes) into engineered systems. It procures steel, tubes, castings and chemicals as primary inputs (INR 5,560 crore of material consumed in FY2026). Downstream, it increasingly captures lifecycle revenue through O&M, digital monitoring and ownership of energy assets (BOO). ### Independent characterisation Thermax is best understood as a diversified Indian industrial-capex proxy with three distinct economic engines: (i) a high-quality, mid-teens-ROCE products franchise (Industrial Products) with strong brand equity in boilers, heaters and absorption chillers and a rising international mix; (ii) a cyclical, execution-sensitive projects business (Industrial Infra/TBWES) whose margins swing with legacy-contract overruns and which is re-entering the thermal power boiler cycle; and (iii) a capital-intensive set of energy-transition bets (BOO steam, open-access renewables, bio-CNG, green hydrogen, chemicals capacity) that have absorbed most of the INR ~3,350 crore of capex since FY2022 but have yet to earn adequate returns. The investment debate is essentially whether engines (ii) and (iii) can be fixed or scaled fast enough to justify a premium multiple anchored in engine (i). ### End-markets served Power (utility and captive), refining and petrochemicals, chemicals, pharmaceuticals and biopharma (high-purity water via TSA), food and beverage, metals and mining, steel, cement, paper and packaging, textiles, sugar and distilleries, rubber, automotive, urban infrastructure, commercial buildings and district cooling, data centres (newly disclosed in FY2026), and construction/tunnelling (construction chemicals). The Q1 FY2027 investor presentation noted consistent order demand from chemicals, food and beverage, and metals and mining. In Q4 FY2026, power accounted for 42% of order booking, driven by the INR ~1,600 crore ultra-supercritical boiler order.

Revenue$1.2B
Employees5,832
Market CapN/A
Founded1966
Maharashtra, India
GCDIS.A.

GCDI S.A.

Premium
Information Technology

GCDI S.A. is the reconstituted form of TGLT S.A., once one of Argentina's most visible premium residential developers. TGLT built the Forum, Astor, Metra and Venice brands. In January 2018 it acquired Caputo S.A.I.C.F., an engineering and construction contractor with roots back to 1938 and more than 500 completed public and private works. After a deep 2019–2020 recapitalization and a 2022 rebrand, management turned the company into a third-party construction contractor and progressively exited own-account real estate development. The contractor platform delivered nationally visible projects: the Más Monumental stadium expansion for River Plate, the new Ezeiza departures hall, the RA-10 nuclear reactor building, and refurbishments of the Plaza and Sheraton hotels. Its finances never stabilized. Consecutive losses, a stalled legacy project (Astor San Telmo), US-dollar notes and peso volatility left equity negative by end-2025. A new controlling shareholder (MFX Holding) and CEO arrived in late 2025 and early 2026, followed by a court reorganization filing in May 2026. GCDI is now a distressed micro-cap whose equity value depends on the outcome of its creditor negotiation. --- ### What the company does GCDI is an Argentine engineering and construction company. It acts mainly as a general contractor ("contratista principal") for third-party private and institutional clients. It also retains a residual portfolio of legacy real estate development assets from the TGLT era. Its activities fall into three groups. **Construction for third parties (core business since 2022).** GCDI bids in private price competitions and public or private tenders to build civil, commercial, hospitality, industrial, sports and infrastructure works. Recent work includes: - stadium expansion (Más Monumental, River Plate); - airport terminals (Ezeiza new departures hall); - hotels (Plaza Hotel, Sheraton Buenos Aires); - industrial plants (Toyota Zárate, Mirgor Baradero); - scientific infrastructure (RA-10 nuclear reactor building); - corporate and residential buildings (Bliss Buenos Aires, OM Recoleta, L'Avenue, Sucre, Aura Núñez, Manzana Concepción); - tourism and leisure (Rueda de Buenos Aires observation wheel in Puerto Madero, Buquebus terminal); - urban public space (Parque Mujeres Argentinas). **Real estate development (legacy, being wound down).** TGLT developed premium and middle-upper-income residential projects in Buenos Aires, Rosario, Tigre and Montevideo. It also acquired land banks such as La Maltería in Hudson. Since 2022 the stated strategy has been to withdraw from projects considered non-core. The main remaining exposure is Astor San Telmo. That project is stalled by litigation, yet it was the largest single asset on the March 2026 balance sheet at ARS 51,661 million. **Engineering services.** When TGLT bought Caputo in 2018, Caputo operated in three segments: construction, real estate development and engineering services (Ámbito, 2018). Engineering and project-management services survive as part of the contracting offer. ### Business and revenue model | Revenue stream | Model | Recognition | Current relevance | |---|---|---|---| | Construction contracts (third parties) | Fixed-price lump-sum ("ajuste alzado") with price redetermination and fixed term; cost-plus and unit-price contracts also typical in Argentina | Over time (IFRS 15, percentage of completion) | Dominant (~all FY2025 revenue, by inference) | | Real estate unit sales | Pre-sales in USD or indexed pesos during construction, with delivery at completion | At delivery (point in time) | Residual | | Engineering services | Fee-based | Over time | Minor; not separately disclosed in sources reviewed | | Land / project disposals | Asset sales | On transfer | Episodic: ARS 16,324M of divestiture proceeds in FY2022 and ARS 6,438M in FY2024 (S&P cash-flow data) | The product/service/subscription/licensing mix is essentially 100% project-based service revenue. GCDI has no subscription or licensing income. Unearned revenue (customer advances) is a large balance-sheet item: ARS 57,431M long-term and ARS 7,944M current at 30 September 2025 (S&P). This reflects pre-sale and advance-payment structures inherited from development projects and contract advances. ### Value-chain position, customers and end-markets GCDI sits in the middle of the construction value chain. It buys steel, cement and energy from suppliers; its largest trade creditors in the concurso include Acindar, Loma Negra and Cementos Avellaneda. It subcontracts specialties and delivers turnkey works to project owners. Its customer types are: - private developers (residential, office, hotel); - industrial corporates (Toyota, Mirgor, UPM in Uruguay); - sports institutions (Club Atlético River Plate); - concession-holders and state-linked entities (airport works at Ezeiza; the RA-10 reactor for Argentina's nuclear programme); - leisure operators (RDBA S.A. for the Rueda de Buenos Aires, a project promoted by Fénix Entertainment). Its end-markets are Argentine private non-residential construction, residential construction, industrial capex and selected infrastructure. Uruguay is a secondary market. ### Company's own description vs. independent characterization **Company framing (paraphrased from public statements and CNV filings).** GCDI describes itself as an Argentine construction group with more than 80 years of history and over 500 completed works. It presents the concurso as a tool to reorder liabilities, keep the business running as a going concern, protect jobs and safeguard assets. It states that works in progress, notably the Rueda de Puerto Madero and the Plaza Hotel, continue. **Independent characterization.** GCDI is a mid-sized general contractor with a strong engineering track record and a weak balance sheet. It is burdened by the residue of a failed premium-development strategy, USD-linked debt and contingent labour and project litigation. Revenue fell 54% nominally in FY2025 and about 67% on a TTM basis to June 2026, so the backlog appears to be shrinking just as insolvency proceedings constrain bonding and supplier credit. The new controlling shareholder brings related-party demand (Fénix Entertainment's Rueda project) and capital-market relationships. Contract-flow revival is therefore plausible, but the concurso proposal will determine value allocation between creditors and existing shareholders.

RevenueN/A
Employees72
Market CapN/A
Founded2005
Ciudad Autónoma de Buenos Aires, Argentina
Terramera

Terramera Inc.

Premium
Information Technology

**Listing status:** The input list describes Terramera as a public company. That is incorrect. Terramera describes itself as privately held [Terramera "About Us" page], and no exchange listing, ticker, ISIN or CUSIP exists for it. Terramera began in 2010 as a neem-based biopesticide start-up. Its first products were consumer and professional bed-bug sprays, the Proof and CIRKIL lines. Over the following decade it built a large patent estate in formulation and active-ingredient delivery, centred on its Actigate™ technology and the IP it bought from Exosect. It raised one of Canada's largest agtech venture rounds (US$48.5M Series B, 2019) on a public goal of cutting synthetic chemical loads in agriculture by 80% by 2030. A financing collapse in mid-2022 forced a strategic reset. Under CEO Nate Kelly, Terramera restructured into what BetaKit (March 2026) describes as an IP holding company. It now incubates and holds equity in independent spinouts: Miraterra, which does soil chemistry, biology and remote sensing, and Catalera BioSolutions, which develops biological fungicides, insecticides and miticides. Terramera's value now rests mainly on its patent portfolio (company-stated at more than 350 patents), its minority and partial stakes in these ventures, and its Indian neem supply operation. Operating revenue is now largely earned by the spinouts. --- **Company's own description.** Terramera's current "About Us" page says the company advances agricultural innovation by building independent, science-based companies. It names Catalera BioSolutions and Miraterra as its spinouts and confirms it is privately held and based in Vancouver. An earlier version of the same page described two internal divisions. The first was "Green Chemistry Solutions," a formulation platform combining machine-learning design, more than 350 delivery and stabilization patents, and rapid prototyping. The second was Miraterra, a soil measurement platform claiming parts-per-million accuracy [Terramera About Us, both versions]. **Independent characterization.** Terramera has gone through three business models. 1. **2010 to about 2016: consumer and professional biopesticides.** The company sold neem-based sprays for bed bugs and dust mites at retail (Proof, sold through retailers including Target) and to pest-control professionals (CIRKIL). It integrated backward into neem supply by buying Plasma Power, an Indian cold-pressed neem oil producer [TechCrunch 2019; PCT Online]. 2. **2016 to 2022: agricultural biologicals and an AI/formulation platform.** Most staff moved to agriculture; by 2019 more than 90% of the team was focused on it [BCBusiness 2019]. The company launched the EPA-registered RANGO (2018) and SOCORO (2023) and licensed and partnered its Actigate delivery technology. It also expanded into digital agriculture and soil-carbon measurement (the Terramera Intelligence Engine), which was heavily grant-funded. 3. **2023 to present: IP holding company and venture builder.** After its 2022 financing fell through, the company split its "many businesses in one" into separately financed spinouts. Miraterra (soil) launched in January 2023 and Catalera (biologicals) in May 2024. Terramera kept equity stakes, the core IP estate and the Indian neem operation [Vancouver Tech Journal, Mar 2023; BetaKit, Mar 2026]. **Revenue model.** Terramera has never disclosed revenue figures; the founder declined to discuss revenue in 2019 [BCBusiness 2019]. Its historical and current revenue types are: **Value-chain position.** Terramera sits upstream, in active-ingredient sourcing (neem and karanja) and in formulation and delivery-technology IP. Through Catalera it reaches crop-protection products sold via distributors to growers. Through Miraterra it reaches measurement infrastructure sold mainly to soil labs rather than directly to farmers [AgTechNavigator, Jul 2025]. **Customer types and end markets.** These are specialty-crop and row-crop growers (organic and conventional), pest-management professionals, consumers (household pests), agricultural input companies (licensing and co-development), soil-testing laboratories, agronomists, and food and supply-chain companies (Miraterra's "soil-to-table" positioning). Government agencies are a further group, as funders and potential standard-setters for soil carbon.

RevenueN/A
Employees29
Market CapN/A
Founded2010
Vancouver, Canada
Ternium

Ternium Argentina S.A.

Premium
Information Technology

Ternium Argentina is Argentina's only integrated flat-steel producer and the domestic cornerstone of Ternium S.A., the Techint Group's Latin American flat-steel platform. From its blast-furnace complex at Ramallo (General Savio, near San Nicolás) and downstream rolling and coating lines at Ensenada, Haedo, Canning and other Buenos Aires sites, it supplies hot-rolled, cold-rolled, galvanised, Cincalum, pre-painted and tinplate products to the automotive, agricultural machinery, white goods, packaging, construction and oil-and-gas value chains. It shipped about 1.9 million tons in 2025, over 97% to the domestic market. Beyond operations, the company is effectively a hybrid industrial holding: it owns 28.7% of Ternium México and a stake in Brazil's Usiminas, which together account for roughly half of its book equity. Its listed equity therefore combines Argentine cyclical steel exposure, Mexican USMCA-linked growth, a large US-dollar-denominated liquidity portfolio and a contingent Brazilian litigation liability. --- ### What the company does Ternium Argentina mines no ore itself; it imports iron ore and metallurgical coal and converts them through an integrated blast-furnace / basic-oxygen-furnace route at Ramallo into slabs, which are hot-rolled and then further processed (cold-rolling, galvanising, electro-galvanising, Cincalum hot-dip aluminium-zinc coating, pre-painting and tin-plating) at Ensenada and other plants. The FY2025 financial statements define three reportable segments: coated rolled products (galvanised, electro-galvanised, pre-painted, Cincalum, tinplate), uncoated rolled products (hot-rolled and cold-rolled sheet/coil), and "other" (mainly slabs, pig iron ingots and overrolling services) (FS FY2025, Note 4). Since January 2026 the company also owns Tubos Argentinos S.A. (TASA), a service centre that converts flat steel into structural and conduction tubes, API-standard pipe, profiles and solar-panel structural components, with plants at El Talar (Buenos Aires) and Justo Daract (San Luis) and roughly 42,000 tons/year of sales. Since 1 January 2025 the company has also absorbed Vientos Olavarría S.A.U., its wholly owned renewable-energy (wind farm) subsidiary, into a single legal entity (merger approved by the Board 14 Feb 2025 and by shareholders 9 Apr 2025) (FS FY2025, Note 1). ### Business and revenue model | Revenue type | Share of FY2025 revenue | Comment | |---|---|---| | Product sales (steel) | ~100% | Revenue is recognised at a point in time on transfer of control, almost entirely direct sales to customers (FS FY2025 Note 3(q)) | | Services (overrolling, processing) | Included in "Other" segment (2.6% of revenue together with slabs/pig iron) | Not separately disclosed | | Subscription / licensing | 0% | The company is a payer, not a recipient, of brand royalties (ARS 24,720M in FY2025, booked in selling expenses) | | Equity-accounted income (non-revenue) | ARS 140,604M in FY2025 | From Ternium México and Usiminas; larger than operating income | ### Value-chain position Ternium Argentina sits mid-stream: it buys imported raw materials (iron ore, coking coal, alloys, industrial gases, natural gas and power) and sells semi-finished and finished flat steel to fabricators, distributors and OEMs. With the TASA acquisition it has moved one step further downstream into tubes and profiles. Its power-cost exposure is partly hedged by own wind generation (Vientos Olavarría), and it holds an O&M contract for that wind farm committing US$53.3M through 2054 (FS FY2025, Note 25). ### Customers and end-markets Management and press coverage identify the following demand drivers: automotive, agricultural machinery, packaging (tinplate), home appliances (línea blanca), construction, and the energy sector — especially oil-and-gas infrastructure tied to Vaca Muerta pipelines — plus mining in northern Argentina (iProfesional, 18 Feb 2026; iProfesional on FY2021 report). In 2025 energy, agro-industry and mining led demand, while international steel prices roughly 20% below the prior year compressed gross margin (iProfesional, 18 Feb 2026). ### Company self-description vs. independent characterisation *Company's own framing (paraphrased from FS FY2025 Note 1 and segment note):* a steel producer whose corporate purpose spans steelmaking, steel product sales, financial investments in other companies, and power generation, organised into coated, uncoated and other products. *Independent characterisation:* Ternium Argentina is better understood as three economic layers in one listed shell: 1. A domestically protected but import-exposed integrated flat-steel mill with thin operating margins (2.4% EBIT margin in FY2025) and high sensitivity to Argentine activity and FX policy; 2. A minority holding in a much larger, more profitable Mexican steel business (28.7% of Ternium México, carried at ARS 3.43 trillion — more than TXAR's entire market capitalisation) plus a small stake in Usiminas; 3. A large treasury book (~US$803M of cash and investments at end-2025, ~US$700M of it in US-dollar-linked Argentine sovereign/Treasury instruments per Ternium S.A.'s FY2025 annual report).

RevenueN/A
Employees5,700
Market CapN/A
Founded1962
Ciudad Autónoma de Buenos Aires, Argentina
Telecom

Telecom Argentina S.A.

Premium
Information Technology

Telecom Argentina is Argentina's largest integrated telecommunications and digital-services operator and, following its February 2025 purchase of Telefónica Móviles Argentina (Movistar), the dominant connectivity platform in the country. It combines a national mobile network (Personal; ~19.4 million Argentine accesses at June 2026), the largest fixed broadband footprint (4.2 million accesses, 36% FTTH), the leading pay-TV and streaming aggregator (Flow; 3.4 million Argentine accesses), corporate/wholesale data, and an expanding digital ecosystem (Personal Pay wallet, now a 50/50 venture with Banco Macro). It also operates in Paraguay (Núcleo, 67.5%), Uruguay (cable), Chile (cybersecurity) and the US (wholesale). Controlled jointly by the Clarín-linked CVH and David Martínez's Fintech, it generates over US$6 billion of pro forma revenue at record-high margins (35.8% in 1H26), but its strategic trajectory now hinges on executing a regulator-imposed divestiture of 6 million mobile customers, 211,400 broadband subscribers and 130 MHz of spectrum. --- **Company's own description (paraphrased from FY2025 earnings release and 20-F).** Telecom describes itself as a leading Argentine telecommunications company combining mobile, cable television, internet and fixed telephony services, plus Fintech services, international long-distance and wholesale, data transmission and IT outsourcing. It provides services in Argentina (mobile, cable TV, internet, fixed and data, fintech), Paraguay (mobile, internet, satellite TV, fintech), Uruguay (cable TV, internet, cybersecurity), the United States (fixed wholesale) and Chile (cybersecurity), positioned as an ecosystem of platforms delivering a convergent customer experience. **Independent characterization.** Telecom is a quad-play incumbent with a structurally recurring, subscription-dominated revenue base. In FY2025, 94.9% of consolidated revenue was service revenue (P$7,902,043 million of P$8,328,814 million), with handset/equipment sales the remaining 5.1%. Within services, mobile is the profit engine (52% of service revenue in FY2025, 55% in 1H26), and 98% of mobile service revenue is mobile data. Fixed broadband and pay TV form the convergent "home" bundle, while fixed voice/data is a declining, partially USD-linked corporate/wholesale line. The company sits at the infrastructure-owning, retail-facing end of the value chain: it owns its access networks (HFC/FTTH, copper legacy, 4G/5G RAN), backbone fiber and data centers, and sells directly to consumers, SMEs, corporates and government, and on a wholesale basis to other carriers. **Customer types and end-markets.** (i) Consumers: prepaid (59% of Personal's Argentine mobile base at June 2026) and postpaid (41%); households for broadband and TV; (ii) SMEs and corporates (Personal Tech: connectivity, cloud, data center, cybersecurity, IoT); (iii) government entities; (iv) wholesale carriers (domestic and international, including a US wholesale subsidiary); (v) fintech users (Personal Pay: 4.7 million users at end-2025; 6.1 million per 2Q26 call commentary). **Unusual governance feature of current operations.** Pending completion of the antitrust remedy, TMA is consolidated but operated at arm's length: Telecom repeatedly states that it does not determine TMA's commercial or pricing policies (FY2025 and 1H26 releases). TMA continues trading as Movistar.

RevenueN/A
Employees17,884
Market Cap$4.8B
Founded1990
General Hornos, Argentina
Tejas

Tejas Networks Ltd

Premium
Information Technology

Tejas Networks is India's only vertically integrated, IPR-owning telecom equipment original equipment manufacturer with a genuinely end-to-end portfolio spanning 4G/5G radio access, converged mobile core, fibre broadband access, coherent DWDM optical transport, IP/MPLS routing, satellite IoT, direct-to-mobile broadcast and in-house software-defined radio silicon. Controlled by Tata Sons through Panatone Finvest, the company converted two decades of optical-transport credibility into a national-scale wireless franchise by delivering more than 100,000 4G/5G RAN sites for BSNL inside roughly eighteen months — an execution feat that made India the fifth country with an indigenously designed, commercially deployed mobility stack. That same concentration is now its central vulnerability: FY2026 revenue collapsed 88% as the BSNL programme wound down, producing a INR 909 crore loss, negative gross profit and INR 3,531 crore of net debt. Tejas today is a technically formidable, financially strained business attempting to convert engineering credibility into diversified, repeatable international demand. --- ### The company's own characterisation The Annual Report 2025-26 describes Tejas as "a pioneering R&D-driven telecom and networking equipment company" that has, since inception in 2000, "focused on innovation in the telecommunications industry, delivering high-performance wireline and wireless networking solutions to customers across more than 75 countries." The stated product scope spans "4G/5G wireless, optical transmission, broadband access, switching and routing, broadcast, and SAT-IoT solutions," serving "telecom operators, internet service providers, utilities, wholesale carriers, and government organizations worldwide." The company's operating ethos is stated as "Designed and Made in India for the World." In the Schedule V disclosure appended to the 26th AGM Notice the company describes its nature of industry more formally as "a global broadband, optical and wireless networking product company, with a focus on technology, innovation and Research and Development," catering to "multiple customer segments" with "an extensive portfolio of leading-edge telecom products for building end-to-end telecom networks based on the latest technologies and global standards with IPR ownership." The stated vision is "to shape the future of trusted networks and mobility"; the stated mission is to "deliver value to our customers globally with intelligent, sustainable and secure networks, with superior execution." ### Independent characterisation Tejas is best understood as a capital-light, R&D-heavy systems designer that outsources electronic manufacturing and monetises intellectual property embedded in hardware. Three structural characteristics define the business model. **First, the value chain position is that of a tier-one network equipment OEM operating an asset-light manufacturing model.** Printed circuit board assembly is outsourced to multiple Electronics Manufacturing Services partners who procure components against Tejas designs, manufacture and test boards. Tejas retains final configuration, system integration, testing and shipment in-house across a 72,000 sq. ft. integration and testing facility supported by a 104,000 sq. ft. warehouse in Bengaluru — more than 200,000 sq. ft. of production and warehousing capacity in aggregate. This preserves gross margin on design IP while limiting fixed manufacturing capital, but it transfers component procurement risk into working capital and makes the company acutely exposed to the timing mismatch between inventory build and order conversion. That exposure is precisely what materialised in FY2026. **Second, the revenue model is overwhelmingly product-led rather than recurring.** The FY2025-26 BRSR discloses that "manufacture of communication equipment and software" accounted for 75.47% of turnover, with "support services" contributing 16.24%. There is no meaningful subscription or licensing line. Annual maintenance contracts attach to large deployments — the BSNL master contract, for example, carries maintenance obligations extending roughly nine years beyond the equipment supply — but these are service annuities on installed base rather than software subscriptions, and they are not separately quantified in public disclosure. The consequence is that revenue is intrinsically lumpy: it recognises on shipment and acceptance of hardware against discrete purchase orders, so a single programme's completion can remove the majority of the revenue base within one fiscal year. **Third, the customer base is narrow, concentrated and heavily policy-mediated.** The company's four functional customer types are (i) telecom service providers and mobile network operators, (ii) internet service providers and fixed broadband operators, (iii) wholesale bandwidth and carrier-of-carrier providers, and (iv) enterprises, utilities, defence and government agencies. In practice a very small number of counterparties have driven results. In FY2025, 94% of revenue came from India-private customers — a figure that reflects TCS as the contracting counterparty for the BSNL programme rather than genuine private-sector diversification. Related-party disclosure in the 26th AGM Notice confirms the mechanism: FY2025-26 sales of goods and services to Tata Consultancy Services were only INR 28.29 crore, and the company sought shareholder approval for TCS transactions of up to INR 4,750 crore in FY2026-27 — equal to 435% of FY2026 consolidated turnover. The revenue engine is therefore effectively a government-funded national infrastructure programme intermediated through a related-party systems integrator. **End-markets served,** as articulated in the FY2026 Annual Report, are: mobile telecom services (4G/5G rollout, modernisation, mobile backhaul); fixed broadband operators (FTTH/FTTB, fixed wireless access); wholesale bandwidth operators (metro and core backbones, leased lines, data centre interconnect, internet exchange points); mission-critical networks (defence, utilities, government, campus, smart cities, private 5G); data centre operators (cloud connectivity, DCI); and satellite and broadcast operators (D2M broadcasting, satellite IoT for fishing vessels, rural last-mile, military communications, railway networks).

Revenue$0.1B
Employees2,229
Market Cap$1.1B
Founded2000
Karnataka, India
Tata

Tata Pigments Ltd.

Premium
Information Technology

The Tata Pigments Limited is one of India's oldest circular-economy businesses. Tata Steel created it to turn acidic waste pickle liquor from its Jamshedpur sheet mills into synthetic iron oxide pigments rather than discharge it into rivers. Nearly a century later TPL remains a small, wholly owned Tata Steel subsidiary. It runs three linked businesses. The first is BIS-licensed synthetic red and yellow iron oxide pigments sold to India's leading paint, building-material, plastics, rubber, paper and ink makers. The second is a downstream line of branded cement paints, flooring colours, primers and putty sold mainly in Eastern India. The third is industrial services: corrosion-protection painting (IDCS) and, since 2019, by-product management, scrap processing and metal recovery for Tata Steel units across India. Its stated ambition is to become a leading integrated mill-services provider in India. Its strategic value to the parent lies less in its own scale than in its role in Tata Steel's circularity agenda. --- ### Company's own description The company describes itself (paraphrased from tatapigments.co.in) as one of India's largest producers of high-quality synthetic iron oxide pigments and the only manufacturer of such pigments holding a Bureau of Indian Standards licence. Its customers are manufacturers of paints, building materials, plastics, rubber goods, paper and inks. It says it launched flooring colours in the 1980s, started making paints in the 2000s, and now offers decorative and industrial paints, industrial coating services and by-product management services. Its stated vision is to grow significantly by expanding its existing businesses and becoming a leading integrated mill-services provider in India. The vision names three focus areas: - corrosion protection and painting services; - sustainable creation of wealth from industrial by-products and wastes; - other mill services. No annual report is published, so there is no "latest annual report" description to reproduce. ### Independent characterisation TPL is best understood as a captive-adjacent industrial ecosystem company. Its three businesses differ in economics: 1. **Synthetic iron oxide pigments (B2B, product).** This is the historical core. Feedstock is iron salt solution from steel pickling, which links input cost and availability to Tata Steel's Jamshedpur operations. In 2012/13 the company converted to a Direct Red Precipitation-cum-Hydrolysis process using US-sourced technology. It also upgraded yellow-oxide seed-making and modernised filtration, drying and blending. It stopped calcination entirely and claims to be the only Indian red iron oxide maker that does not calcine. Customers are formulators: the company's site lists Berger, Asian Paints, Beckers, BlueScope and others as clients. 2. **Decorative products (B2B2C, branded product).** This is forward integration that began in the mid-1990s with cement paints under the brands Cemplus and Ecocem. It later expanded into flooring colours (e.g., "Tata Red Value"), red oxide metal primer, water-based primer ("WallplusLite") and wall putty. The company says these products hold a significant share in niche Eastern Indian markets. They are sold through a dealer network and lean on the Tata brand. 3. **Industrial services (B2B, service).** - *IDCS (Industrial Decorative & Coating Services):* industrial painting and corrosion-mapping solutions for plants and large projects. The company calls itself one of the largest corrosion-mapping and painting solution providers in Eastern India. - *By-product management (since 2019):* scrap processing, recycling and metal recovery for steel and metal industries. It serves all Tata Steel units across India, which makes Tata Steel the anchor customer. **Revenue model mix:** product sales (pigments plus decorative products) and service contracts (IDCS plus by-product management). There are no subscription or licensing revenues. The exact product/service split for recent years is not publicly disclosed. The last public datapoint is FY2015, when IDCS contributed about INR 20 crore of roughly INR 100 crore total turnover (≈20%) (Tata Steel / MoneyWorks4Me, 3 April 2015). **Value-chain position:** upstream specialty chemicals (pigment intermediate), mid-stream branded building chemicals, and downstream plant services. TPL both buys from Tata Steel (pickle liquor, slag, scrap streams) and sells to it (services). This creates high related-party intensity. **End-markets:** decorative and industrial paints and coatings; construction materials (concrete, pavers, tiles, flooring); plastics and rubber; paper; printing inks; steel and metals (services).

RevenueN/A
Employees171
Market CapN/A
Founded1927
Jharkhand, India
T&KTOKA

T&K TOKA Corporation

Premium
Information Technology

T&K TOKA is a mid-sized Japanese specialty-ink and functional-materials maker. Its main franchise is ultraviolet (UV)-curable printing inks, a technology it commercialised in 1977. The company describes itself as Japan's market-share leader in UV inks. Bain Capital singled out that leadership as the core of its investment thesis. Around the ink base sit two adjacent platforms: **Functional resins:** epoxy hardeners, latent curing agents and dimer-acid thermoplastic resins. **Precision dispersions:** colour-filter pigment dispersions for flat-panel displays, with a dedicated plant in Zhejiang, China. Overseas operations are Asia-centric, with subsidiaries in Korea, Indonesia, Thailand, China and the US. The company also holds a roughly 30% equity-method stake in Hangzhou Toka Ink, which is listed on Shanghai's STAR Market. The financial profile is weak. Consolidated revenue fell from ¥49.6bn (FY3/2019) to ¥43.7bn (FY3/2023), and operating margins stayed near 1%. Activist pressure from Dalton/NAVF followed, and in 2024 Bain took the company private. The equity story now rests on a privately executed turnaround under an externally recruited CEO. --- ### Company's own description (FY3/2023 Yuho, paraphrased) | Product type | Main uses | |---|---| | UV inks | Cartons, labels, cards, pamphlets, cans | | Planographic / offset inks | Posters, catalogues, magazines, flyers | | Flexographic inks | Labels, paper bags, corrugated boxes | | Gravure inks | Frozen-food and confectionery bags, publications | | Metal-decorating inks | Food, beverage and art cans | | Special functional inks | FPDs, electronic substrates | | Functional resins | Bridge anti-corrosion paints, automotive adhesives, metal coatings, ink binders, functional films, FRP | The group makes and sells: - printing inks (offset, gravure and others); - printing machines and printing-related equipment such as blankets; - functional resins; - precision dispersion products. It reports as a single segment ("printing ink business"). No segment-level breakdown is therefore disclosed. The FY3/2023 Yuho lists seven main product types: ### Independent characterisation | End-market | Stated trend | |---|---| | Publication printing | Declining | | Commercial printing | Flat | | Package printing | Growing, with sustainability the dominant theme in every field (Yuho FY3/2023) | T&K TOKA is a B2B formulator and manufacturer. Revenue is overwhelmingly product sales: the FY3/2023 Yuho reports production of ¥32.7bn at selling-price value and purchased merchandise of ¥6.0bn. There is no meaningful subscription or licensing revenue. The approximate revenue mix (derived, FY3/2023) is: - about 85% manufactured products; - about 15% traded merchandise such as consumables and equipment (inferred from the purchased-goods figure). **Value-chain position.** The company sits in the middle of the chain: **Upstream:** it buys pigments, crude-oil derivatives, imported vegetable oils and monomers. Dainichiseika and Nagase are named as purchasing partners in its cross-shareholding disclosure. **Downstream:** it sells inks to printers and converters (commercial, label, carton and flexible-packaging printers, can makers). It sells resins to paint, adhesive and composites makers, and dispersions to display-materials supply chains. **Customer types.** Shareholdings held "to strengthen sales relationships" provide indirect evidence: - printing majors: Dai Nippon Printing, Toppan, Kyodo Printing; - packaging printers: Asahi Printing, Nozaki Insatsu Shigyo, Takeda Printing; - NISSHA; - Kansai Paint (a resin customer); - Shobond Holdings (bridge-repair coatings, consistent with anti-corrosion epoxy hardeners); - Oji Holdings. IR Bank's profile lists Nikka Fine Techno and JSR as principal customers, consistent with the display-materials business. **End-markets.** The company also serves electronics/display (colour-filter dispersions, special inks) and industrial coatings/adhesives/composites (resins). ### Business model economics Gross margins sat in a narrow 17–19% band (FY3/2019–FY3/2023, EDINET DB calculation from Yuho data). Operating margins of 0.5–1.1% show that SG&A absorbs nearly all gross profit. Pre-tax profit therefore depended heavily on non-operating income: equity-method income, mainly from Hangzhou Toka Ink, plus dividends from cross-shareholdings and FX gains. For example, in FY3/2023: - operating income was ¥424M; - ordinary income was ¥1,853M; - the ¥1.43bn gap was largely equity-method and other non-operating income. This structure, a low-return core business supported by an associate stake and portfolio investments, is central to understanding both the activist campaign and the take-private.

Revenue$0.3B
Employees1,122
Market CapN/A
Founded1947
Saitama, Japan
T.Hasegawa

T. Hasegawa Co., Ltd.

Premium
Information Technology

T. Hasegawa is Japan's second-largest flavour and fragrance (F&F) house and the world's tenth-largest by the company's own estimate, with FY2025 consolidated net sales of ¥73.5 billion (≈US$491 million). Unlike diversified peers, it is a near pure-play in high value-added *compounded* flavours, which generated 89.6% of FY2025 sales, with fragrances making up the balance; it does not sell commodity aroma chemicals externally at scale. The model is built on a large library of proprietary formulas developed by flavourists and perfumers (roughly a decade to train), high-mix manufacturing of about 12,000 products a year, and deep integration with Japanese beverage, dairy, snack, instant-noodle and seasoning makers. Its three-pole footprint — Japan (earnings base), China/Southeast Asia (high-margin growth) and the USA (scale-building via M&A) — is underpinned by a fortress balance sheet (83.5% equity ratio, effectively no debt). The principal debate is capital efficiency: ROE of 5.7% and a P/B near 1.0x. --- ### What the company does T. Hasegawa researches, develops, manufactures and sells flavours (food and beverage aromas) and fragrances (scents for cosmetics, toiletries and household products). Its upstream capabilities include synthesis of aroma chemicals, extraction of natural aromatics (including supercritical CO2 extraction at Fukaya since 1989), and analysis; the commercial output is overwhelmingly *compounded* products — formulations created to a customer's brief by blending natural and synthetic materials. Product formats span liquid compounded flavours, emulsified flavours, powdered flavours, natural extracts, processed fruit products and natural colourants [HIST], [MHLW-ITAKURA]. ### Company's own description (paraphrased from FY2025 disclosures) In its FY2025 results and Securities Report, the company describes itself as a group that manufactures and sells various flavours and fragrances, giving primary weight to quality control and product safety, continually improving research and technology development, and concentrating on unique, high-quality, high value-added products. It frames its long-term mission as enriching lifestyles and contributing to a sustainable society through aroma and adjacent technologies [TANSHIN-FY25], [PRES-H1FY26]. ### Independent characterisation T. Hasegawa is a mid-cap, B2B specialty-ingredients business whose economic moat rests on three things: (1) formula IP and tacit know-how embedded in its flavourists' libraries, which creates switching costs once a flavour is specified into a customer's SKU; (2) co-development intimacy with Japanese consumer-goods companies, where it holds an 18.8% share of the domestic top-10 F&F market; and (3) regulatory and quality infrastructure (FSSC 22000, ISO 9001) required by food majors [PRES-H1FY26], [SR-2025]. Its weakness relative to the global "Big Four" is scale: it lacks the global key-account "core list" status that multinationals use to restrict suppliers, which is why its overseas growth is concentrated in China, Southeast Asia and mid-sized US accounts rather than global FMCG majors. ### Revenue model | Revenue model element | Description | Share / evidence | |---|---|---| | Product sales (point-in-time) | Custom and catalogue flavours and fragrances sold per kg/lot to manufacturers; revenue recognised at transfer of goods | ~100% of revenue; the segment note states revenue is mainly goods transferred at a point in time [TANSHIN-FY25] | | Services | Application development, sensory evaluation, trend reports — bundled into product pricing, not separately billed | Not separately disclosed | | Subscription / licensing | None disclosed | 0% | | Processed food materials | Nut and fruit processing (Hasegawa Business Service's FC division) — small | Included in flavour sales; not separately disclosed | ### Value-chain position T. Hasegawa sits in the middle of the food and personal-care value chain: it buys essential oils, botanicals, petrochemical-derived solvents and aroma chemicals, adds formulation IP and processing, and sells to branded consumer-goods manufacturers. It is invisible to consumers. Pricing power derives from small ticket size relative to the customer's final product cost (flavour is a low single-digit share of a beverage's COGS) combined with high reformulation risk for the customer. ### Customer types and end-markets | Region | Flavour focus | Fragrance focus | |---|---|---| | Japan | Broad beverage and food usage; raw-material replacement flavours; health/medical foods | Cosmetics, household; odour masking; environmentally friendly fragrances | | USA | Savoury, beverage, health; sweet flavours (Mission); Midwest via ABELEI | Not entered | | China | Beverages and instant noodles; international and local customers | Household products (toiletry makers) | | Southeast Asia | Flavour powders and beverage flavours; Vietnam PMI; Philippines expansion | Body care, served by exports from Japan | Source: [PRES-H1FY26]. The equivalent FY2024 split was beverages ~33%, dairy ~24%, snacks ~12%, seasonings ~11%, instant noodles ~9%, other ~11% [PRES-FY24]. Beverage exposure makes sales seasonal (stronger in the second half) and sensitive to summer weather. Regional end-market emphasis per management's portfolio map [PRES-H1FY26]: No single customer exceeds 10% of consolidated sales [TANSHIN-FY25].

Revenue$0.5B
Employees1,942
Market CapN/A
Founded1903
Tokyo, Japan
Sunshow

Sunshow (Yangzhou) Chemical Co., Ltd.

Premium
Information Technology

Anhui Sunshow Chemical is a mid-sized, privately held Chinese specialty-chemicals producer focused on polymer stabilization — hindered amine light stabilizers (HALS), UV absorbers, antioxidants, polymerization inhibitors and an expanding set of functional monomers and anti-corrosion additives. Operating from three domestic production bases with roughly 300 staff, it sells under the SUNOVIN®, SUNOX®, SUNORA, SUNOBLE® and PHOSMER brands, and exports more than half its output to Europe and North America, largely through a Yantai commercial arm and a Hong Kong trading affiliate. The company is a second-tier challenger in a global market led by BASF, Songwon, Clariant/Tiangang, Adeka and SI Group, and by large Chinese integrated producers such as UniteChem and Rianlon. Its differentiation rests on partial backward integration into HALS intermediates (TAA, TMP, TAD) at Hebi, a broad commodity-to-specialty catalogue offered at Chinese cost levels, and a growing push into anti-corrosion, coatings and new-energy additives. --- ### Company's own description The company describes itself (website, current) as a high-tech enterprise integrating R&D, production and sales of functional new-material products, and as a principal producer of special additives for new materials. Its stated core product matrix covers light stabilizers, UV absorbers, phosphate-ester monomers, special additives for nylon, polyurethane additives and polymerization inhibitors. It lists applications in degradable plastics, coatings, rubber, chemical fibres, adhesives, polyurethane and lithium-battery electrolyte, among other specialty chemicals. Its corporate mission slogan is "Adding value to polymers" (为聚合物添加价值), and it presents itself as working towards becoming a leading supplier to the global plastics, rubber, fibre, adhesive and coatings industries. The international storefront (Knowde, "Sunshow (Yan Tai) Specialty Chemical") adds that the company specializes in light stabilizers, UV absorbers and antioxidants, has a strong reputation domestically and abroad, and exports over half its products to developed markets in Europe and the US. ### Independent characterization | Value-chain stage | Sunshow participation | Evidence | |---|---|---| | Petrochemical feedstocks (acetone, ammonia, phenols, phosphorus chemicals) | Buyer | Inferred from product chemistry | | HALS intermediates (triacetonamine TAA, tetramethylpiperidinol TMP, 4-amino-TMP/TAD, DMS) | Producer (Hebi) — partial backward integration | 2020 Hebi EIA: 8,000 t TAA, 4,000 t TMP, 1,000 t TAD, 1,000 t DMS | | Finished stabilizers (HALS, UVA, antioxidants, inhibitors) | Core business | 2026 EIA existing capacities; product catalogues | | Masterbatches / compounded granules (anti-corrosion masterbatch, compounded pellets) | Emerging | 2026 EIA: 5,000 t anti-corrosion masterbatch, 1,000 t compounded granules | | Compounders, masterbatch makers, coatings formulators, fibre producers | Customers | Website industry-solutions pages | | OEM end-markets (automotive, appliances, agriculture, construction/WPC, packaging, cable, pipelines) | Indirect | Website industry-solutions pages | | End-market | Applications listed by company | |---|---| | Automotive | Instrument panels, bumpers; seals, wiper parts; engine-bay and cooling-circuit parts; radiator grilles; seat cushions, steering wheels; lamp frames | | Home appliances | Appliance films; appliance housings | | Agriculture | Films, pipes, tapes | | Wood-plastic composites | Outdoor landscaping; indoor decorative materials | | Packaging & textiles | FIBC bulk bags; nonwovens; artificial turf yarn | | Coatings & paints | Waterborne; solvent-borne | | Cable & anti-corrosion | Buried plastic-coated steel pipe; general cable | | Polymerization inhibitors | Monomer production and storage | Sunshow is best characterized as a B2B intermediate-to-specialty additives manufacturer occupying the middle of the polymer value chain: **Revenue model.** Revenue is overwhelmingly product sales (per-tonne/per-kg pricing of chemical additives), sold B2B both directly and through distributors and overseas agents (a new European agent agreement was signed at ChinaPlas 2016 per company news). There is no evidence of service, subscription or licensing revenue. Technical service (formulation support, technical documentation) is bundled into the sale. The mix between direct and distributor sales, and between domestic and export, beyond the ">50% export" statement, is not publicly disclosed. **Customer types.** Plastics compounders and masterbatch producers; coatings and paint formulators (waterborne and solvent-borne); fibre and nonwovens producers (FIBC bags, nonwoven fabrics, artificial turf yarn); wood-plastic composite (WPC) manufacturers; agricultural film, pipe and tape producers; cable and anti-corrosion coated steel-pipe makers; polyurethane and adhesive manufacturers; monomer producers needing polymerization inhibitors; and, per the company, lithium-battery electrolyte producers. A 2017 US customs record shows Maroon Inc. (a US specialty-chemical distributor) receiving goods from the Hong Kong affiliate. **End-markets served (company's eight "industry solutions").**

RevenueN/A
Employees300
Market CapN/A
Founded2016
Anhui Province, China
Stockhausen

Stockhausen Inc.

Premium
Information Technology

Stockhausen is one of the oldest names in Western superabsorbent polymer manufacturing. It is a backward-integrated producer of SAP and its key feedstock, acrylic acid. Its Krefeld site ran the world's first large-scale SAP plant in 1986, and its FAVOR® brand was in more than 40 billion diapers a year by 2011. After almost two decades inside Degussa and Evonik, the business returned to independence under private-equity-style ownership. ICIG bought it in August 2024 as a standalone "Superabsorber platform" and revived the heritage name. Stockhausen sells only to other businesses. Its customers are global hygiene converters (baby diapers, feminine care, adult incontinence) and niche technical markets: cable water-blocking, swellable elastomers, agricultural water retention and food-packaging pads. The business has strong application-technology know-how, but it competes in a commoditising, Asia-weighted market. By Evonik's account, it earned thin margins, averaging around €20 million of adjusted EBITDA a year over 2019–2023 on sales of about €0.9 billion. Its investment case rests on a carve-out turnaround, bio-based products and cost discipline. --- ### Company's own description On its website, Stockhausen calls itself a global manufacturer of superabsorbers that has been "keeping things dry" for more than 40 years. It says its products serve people across the life course: baby diapers, menstrual care and incontinence products, plus agricultural and industrial uses where moisture control matters. Acrylic acid is described as the core of its technology. The company makes acrylic acid for its own SAP and sells some to outside customers. It states that it has belonged to ICIG since 2024 and that it sells B2B only [Source: stockhausen.com About Us and Products, accessed Oct 2026]. ICIG presents Stockhausen as its superabsorber platform, formed in 2024. In ICIG's description, the platform has five manufacturing sites in Europe and the US (an acrylic acid plant in Marl plus SAP plants in Krefeld, Rheinmünster, Greensboro and Garyville) and two R&D and innovation centres in Greensboro and Krefeld. ICIG calls it a full-service supplier to the SAP industry and a leader in application technology [Source: ic-investors.com Stockhausen platform page]. ### Independent characterisation Stockhausen is an integrated, mid-tier commodity-to-semi-specialty polymer producer. Its economics depend on three spreads: **Propylene to acrylic acid:** at Marl. **Acrylic acid to SAP:** across the four SAP plants. - **SAP list prices**, which are set through contracts with a concentrated customer base of global diaper makers and private-label converters. The hygiene grades, mainly FAVOR®, almost certainly make up the large majority of volume and revenue. The technical grades (CABLOC®, CREABLOC®, STOCKOSORB®, FAVOR® Pac) carry higher unit value but are small in tonnage. No product-level split is disclosed. ### Business model and revenue model | Revenue type | Description | Estimated weight | Basis | |---|---|---|---| | Product sales: hygiene SAP (FAVOR®) | Tonnage contracts with diaper, feminine-care and incontinence manufacturers | Dominant (exact share not disclosed) | stockhausen.com; Evonik described the unit as "superabsorbents for diapers and hygiene" | | Product sales: technical SAP | CABLOC® (cable), CREABLOC® (elastomer seals, downhole packers), STOCKOSORB® (horticulture/agriculture), FAVOR® Pac (food pads) | Minor (not disclosed) | stockhausen.com Products | | Product sales: merchant acrylic acid | Surplus acrylic acid from Marl sold to paints, coatings and flocculant producers | Minor (not disclosed) | stockhausen.com Products | | Services | Application technology and co-development with customers, bundled into product pricing rather than billed separately | Not separately monetised | stockhausen.com; Evonik 2015 application-centre release | | Licensing / subscription | None disclosed | — | — | ### Value-chain position The company buys propylene, a petrochemical feedstock, and supplies the Marl acrylic acid plant from it. Marl sits in Chemiepark Marl, a large integrated chemical park. The SAP plants then polymerise and crosslink acrylic acid with caustic soda into SAP granulate. Customers are converters: branded diaper makers and private-label producers. Stockhausen does not sell to consumers. ### Customer types and end-markets | End-market | Products | Customer type | |---|---|---| | Baby care (diapers) | FAVOR® | Global and regional diaper OEMs, private-label converters | | Feminine care | FAVOR® | Hygiene converters | | Adult incontinence | FAVOR® (including odour-control grades) | Hygiene converters, medical-supply brands | | Food packaging | FAVOR® Pac (FDA-cleared and EU food-contact compliant) | Absorbent pad makers, meat and poultry packers | | Wire and cable | CABLOC® | Power and telecom cable makers | | Civil engineering, oil and gas, geothermal, mining | CREABLOC® | Rubber compounders, makers of swellable seals and packers | | Horticulture and agriculture | STOCKOSORB® | Nurseries, greenhouses, roof-greening and vertical-farming operators | | Coatings, paints, flocculants | Acrylic acid | Chemical producers |

Revenue$1.0B
Employees1,000
Market CapN/A
Founded1873
Krefeld, Germany
Stahl

Stahl Holdings

Premium
Information Technology

Stahl is a Dutch-headquartered formulator of speciality coatings for flexible materials — leather, synthetic leather and textiles, and paper/film packaging and labels. Its products are largely invisible to consumers but determine how a car seat, handbag, shoe upper or premium package looks, feels and wears. After two decades of private-equity ownership under Wendel, the company completed a multi-year pivot from a broad leather-chemicals supplier into a pure-play coatings formulator: it bought Clariant's and BASF's leather businesses (2013–2017), added packaging coatings through ICP Industrial Solutions Group (2023) and WEILBURGER Graphics (2024), and then carved out its wet-end leather chemicals into Muno (effective 1 January 2026). The resulting business, roughly €725m of 2025 adjusted sales with an asset-light, service-intensive model and a majority of revenue from water-based technologies, was acquired by Henkel for an enterprise value of €2.1bn and closed on 1 October 2026, giving Henkel's adhesives unit an adjacent coatings platform. --- ### What the company does Stahl develops, formulates, manufactures and applies coatings and surface treatments for flexible substrates. Its own description (stahl.com, 2026) positions it as the provider of speciality coatings behind everyday materials in automotive, apparel, luxury goods, footwear, packaging and home furnishings, organised in three business lines: Performance Coatings, Leather Finishing and Packaging Coatings (PCI Magazine, June 2026, citing Stahl). Henkel's description of the acquired portfolio is identical in substance: leather finishing coatings, performance coatings, and high-performance paper packaging and graphics coatings (Henkel release, 4 Feb 2026). ### Business and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Product vs service mix | Overwhelmingly product revenue (formulated chemicals sold by weight), but the value proposition is service-heavy: application laboratories, on-site technical specialists, colour matching and customisation | Henkel's Adhesive Technologies head described the model as asset-light, know-how-based and service-driven with a high degree of customisation (Henkel, 4 Feb 2026) | | Subscription / licensing | No disclosed subscription or licensing revenue | Not publicly disclosed | | Technology mix | Majority of revenue from water-based solutions (Henkel, Feb 2026). Stahl's 2024 ESG report stated that more than 50% of 2024 revenue (excluding Packaging Coatings) came from water-based products | Stahl 2024 ESG report release, Apr 2025 | | Asset intensity | Formulation and blending rather than base-chemical production; raw materials (resins, polyurethanes, acrylics, pigments, solvents) bought in, with some in-house polymer/PUD production (e.g. Singapore PUD plant, 2024) | Stahl, Oct 2024 | ### Value-chain position Stahl sits between bulk raw-material suppliers (petrochemical and polymer producers) and converters — tanneries, synthetic-leather and coated-textile manufacturers, printers and packaging converters. Crucially, demand is often prescribed by end brands (automotive OEMs, luxury houses, sportswear and consumer packaged goods companies), who specify finishes that converters must then buy. Wendel's December 2024 investor-day deck explicitly framed premium brands as "prescribers" for Stahl's direct customers. This prescriber dynamic is a key source of switching costs. ### Customer types and end markets | Customer type | Examples of applications | Source basis | |---|---|---| | Tanneries (finishing stage) | Automotive leather, luxury leather goods, footwear, upholstery | Stahl Leather Solutions pages | | Synthetic leather / coated fabric producers | PU-coated fabrics for footwear, apparel, automotive interiors | Stahl site; Permuthane heritage | | Packaging converters and printers | Barrier, overprint and functional coatings for paper, labels, folding cartons, flexible packaging, especially food and pharma | ICP ISG acquisition releases (2023); WEILBURGER (2024); Repura launch (2026) | | End brands (indirect, as prescribers) | Automotive OEMs, luxury and fashion houses, footwear brands | Wendel deck, Dec 2024 | End markets named consistently: automotive/mobility, fashion and lifestyle, luxury, footwear, packaging, home furnishings (Wendel company page; Henkel releases). ### Independent characterisation Stahl is best understood as a niche formulation franchise with three distinct demand engines: (1) leather finishing, a mature but highly concentrated niche where Stahl is the global leader and earns premium pricing through regulatory compliance and technical service; (2) performance coatings for synthetic and textile substrates, which benefits from substitution toward synthetic materials and solvent-free PU technology; and (3) packaging coatings, the newest and most acquisition-built engine, levered to plastic-to-paper substitution. Its earnings were historically resilient (EBITDA margins of roughly 21–23% through 2022–2023 on Wendel's figures), but volumes are cyclical and tied to automotive and luxury production, as the 2023 and 2025 slowdowns demonstrated.

RevenueN/A
Employees1,700
Market CapN/A
Founded1930
PE Waalwijk, Netherlands
Songwon

Songwon Industrial Co., Ltd.

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Legal name | Songwon Industrial Co., Ltd. | [S1], [S14] | | Korean name | 송원산업 | [S20] | | Group name used in reporting | SONGWON Industrial Group | [S1] | | Former names | None identified in company history materials | [S14] | | Founding year | 1965, with the first head office and plant in Busan | [S14] | | Founder | Kyoung-jae Park (father of the current Group CEO) | [S14] | | Incorporation jurisdiction | Republic of Korea | [S14] | | Headquarters | Ulsan, South Korea. The head office moved from Busan to the Ulsan plant in March 1988. A full street address was not captured in the sources reviewed. | [S14], [S16] | | Listing | KOSPI (Korea Exchange); listed June 1977 | [S14], [S20] | | Ticker | 004430 (also shown as A004430 or KRX:004430) | [S20], [S21] | | ISIN | KR7004430006, based on the standard KRX ISIN convention. Not confirmed in a primary filing during this research; verify before relying on it. | Analyst | | CUSIP | Not applicable (no US listing) | — | | Shares outstanding | Approximately 24.0 million common shares | [S22] | | Fiscal year end | 31 December | [S22] | | Group auditor | Samjong KPMG (named as group auditor in the 2025 and 2026 preliminary reports) | [S23] | | Employees, FY2021 | 1,015 (head count) | [S16] | | Employees, FY2022 | 994 (head count) | [S16] | | Employees, FY2023–FY2025 | Not publicly disclosed in the sources reviewed. The FY2025 Annual Report and the Korean DART business report should contain the figure. | — | | Market capitalization | About KRW 270–290 billion in July–August 2026. The share price of about KRW 11,460 on 31 Aug 2026 implies roughly KRW 275 billion on 24.0M shares. | [S22], [S24], [S25] | | Website | https://www.songwon.com | [S1] | | Investor contact | ir@songwon.com | [S2] | The entity profiled is Songwon Industrial Co., Ltd. (송원산업주식회사), the parent company of the SONGWON Industrial Group. It is headquartered in Ulsan, South Korea, its website is www.songwon.com, and it is a public company listed on the Korea Exchange (KOSPI). SONGWON is a family-controlled Korean specialty chemicals company. It describes itself as the world's second-largest producer of polymer stabilizers, the antioxidants and light stabilizers that stop plastics from degrading during processing and use [S16]. The core franchise is the SONGNOX® phenolic and phosphite antioxidant range, sold both as single components and as customised One Pack System (OPS) blends that polyolefin producers dose directly into their reactors and extruders. The group adds fuel and lubricant additives, coatings raw materials (photoinitiators and UV absorbers), organotin intermediates and PVC stabilizers, thermoplastic and solution polyurethanes, and specialty chemicals. Production is integrated across Korea, China, India, Germany, the UAE and the US, with a Swiss management hub. The business is cyclical and tied to petrochemical feedstock costs. Revenue sits around KRW 1.0–1.3 trillion, and operating margins have ranged from about 2% to 14% over five years. H1 2026 brought a sharp profit recovery as supply disruption linked to the Middle East tightened additive markets [S5], [S15]. --- ### What the company does SONGWON develops, manufactures and sells additives and intermediates. Its products are used in small quantities inside much larger material systems: polyolefin resins, engineering plastics, PVC, lubricants, fuels, UV-cured coatings, adhesives, textiles and footwear. The company organizes its portfolio into six product groups [S16]: 1. Polymer Stabilizers 2. Fuel and Lubricant Additives 3. Coatings 4. TPU/SPU (thermoplastic and solution polyurethanes) 5. Tin Intermediates/PVC 6. Specialty Chemicals These roll up into two reporting divisions. Industrial Chemicals contains Polymer Stabilizers, Fuel & Lubricant Additives and Coatings. Performance Chemicals contains Tin Intermediates/PVC, TPU/SPU and Specialty Chemicals [S16]. ### Company's own description In its standard corporate boilerplate (FY2025–FY2026 press releases), SONGWON presents itself as a leader in developing, producing and supplying specialty chemicals, whose products reach consumers' daily lives. It says it has offered customised "360°" solutions since 1965. It positions itself as one of the world's leading polymer stabilizer manufacturers and states that it serves customers in more than 60 countries [S18]. Its stated vision is to be a global leader in specialty chemicals with solid and sustainable growth. Its mission is to be the "supplier of choice" through service, quality, competitiveness, innovation and customised solutions [S17]. ### Independent characterization Analytically, SONGWON is a mid-cap, product-led, B2B additive manufacturer. Its economics behave more like a semi-commodity intermediate producer than a high-margin formulator: **Revenue model:** Almost all revenue comes from product sales, invoiced per kilogram. Licensing and subscription revenue is negligible. Service content such as technical service, regulatory support and application development is bundled with the product and not charged separately [S16]. **Pricing mechanics:** Fuel & Lubricant Additives uses formula-based pricing. Tin Intermediates revenue moves with tin ingot prices. Polymer Stabilizers and Coatings prices are reset through periodic list-price actions. Examples in 2026 are the 12–20% global increase announced on 11 March 2026 and the further increases announced on 9 April 2026 [S5], [S9], [S10]. **Value-chain position:** SONGWON sits between upstream petrochemical feedstocks (phenol, isobutylene and related intermediates, the main raw-material sensitivity noted by Korean market commentary) and resin producers and compounders. Its largest single customer group appears to be global polyolefin producers buying OPS blends, which is why it builds OPS plants next to petrochemical clusters in Abu Dhabi, Qingdao, the US and, from 2028, Saudi Arabia [S12], [S26]. **Customer types:** Resin producers (PE, PP), compounders and masterbatchers, lubricant blenders and fuel refiners, coatings and ink formulators, PVC processors, footwear, adhesive and textile manufacturers (TPU/SPU), and catalyst users (tin compounds) [S5], [S16]. **End markets:** The company lists eleven: adhesives, agriculture, automotive, building & construction, coatings, durable & consumer goods, electrical & electronics, fuels & lubricants, packaging, textile & fibers, and wire & cable [S1]. ### Revenue mix by model | Revenue model | Share of revenue | Comment | |---|---|---| | Product sales | ~100% | All reported revenue is "sales of goods" [S16] | | Services | Not separately disclosed | Technical and regulatory services bundled with products | | Licensing / royalties | Not disclosed; assumed immaterial | — | | Subscription | None | — |

Revenue$0.7B
Employees994
Market CapN/A
Founded1965
Ulsan, South Korea
SKKaken

SK Kaken Co., Ltd.

Premium
Information Technology

**Profiled entity confirmation:** The entity profiled is SK Kaken Co., Ltd., Ibaraki, Osaka, Japan (www.sk-kaken.co.jp), an active public company listed on the TSE Standard Market (code 4628). This matches the supplied name and the supplied type ("Public company"). It is unrelated to Korea's SK Group. SK Kaken is Japan's leading specialist manufacturer of architectural finishing coating materials (建築仕上塗材) — textured, decorative and high-durability wall finishes, weather-resistant topcoats, roof, floor, waterproofing and anti-corrosion paints — and, secondarily, of ceramic-based fireproof coverings and non-combustible insulation. Its annual securities report describes the core business as holding the No. 1 domestic position. The company is founder-family controlled (the Fujii family and its holding entity own roughly 41% of issued shares), conservatively managed, and essentially debt-free, carrying over JPY 100 bn of cash, deposits and securities against JPY 3 bn of short-term borrowings. Revenue reached a record JPY 109.7 bn in FY2026, with a stable ~11–12% operating margin, and roughly 15% of sales from manufacturing and distribution operations in Singapore, Malaysia, Thailand, Indonesia, Hong Kong and China. Its strategic thrust is to monetise Japan's enormous renovation stock through premium, longer-life coatings, and to ride data-centre and redevelopment demand in fireproofing. --- ### What the company does — company's own description According to the FY2026 Annual Securities Report, the group comprises the parent company plus 12 overseas and 2 domestic subsidiaries, and is principally engaged in manufacturing and selling architectural finishing coating materials and fireproof/insulation materials. It reports three segments: (i) Architectural Finishing Materials — organic-inorganic water-based coating materials, synthetic-resin paints, inorganic paints and inorganic building materials, together with specialist finishing construction work; (ii) Fireproof Insulation Materials — insulation, fireproof covering materials and fire-resistant paints, plus fireproofing and insulation installation work; and (iii) Other — cleaning agents and thinners. The company's management philosophy is framed around the founding spirit "creating something from nothing" (無から有) and seven product themes: environmental improvement, enhancement of asset value, labour saving, comfort, health, safety and peace of mind. Management describes the ambition to become an "only-one, number-one" global comprehensive chemical coatings and building-materials manufacturer contributing to the building culture of Japan and Asia. ### Business model SK Kaken is a vertically integrated formulator-manufacturer. It formulates proprietary coating systems in two in-house research institutes, manufactures them in seven domestic plants and five overseas plants, and sells primarily through distributors (paint dealers) and specialist painting/installation contractors to construction companies, housebuilders and building owners, while specifying products into projects via design offices (architects). Because the product only becomes a finished good once applied as a coating film, the company bundles extensive technical services: specification support, seminars for designers, general contractors, dealers and applicators, internal training to equip staff to advise customers, and on-site follow-up from sale through completion. The company states that business funds are covered from internal resources (debt-free management). ### Revenue model mix | Revenue type | Description | Disclosure status | |---|---|---| | Product sales | Coating materials, fireproofing materials, insulation, thinners/cleaners — the overwhelming majority of revenue | Not separately quantified | | Construction / installation services | Specialist finishing work (parent, SKK(S), SK Coatings, SKK(H'K), SK Kaken (Thailand), PT SKK Kaken Konstruksi) and fireproofing/insulation work (parent, Shanghai) | Included in segment sales; not separately disclosed | | Subscription / licensing | None disclosed | Not applicable | Order-to-delivery lead times are short, so the company does not disclose order backlog (Yuho FY2026). No single customer exceeds 10% of sales. ### Value-chain position Upstream inputs are predominantly petrochemical derivatives (acrylic, silicone, fluorine and urethane resins, solvents, emulsions), pigments (titanium dioxide), inorganic fillers, aggregates and ceramic materials. The company sits in the mid-stream as formulator and manufacturer; downstream it relies on dealers and applicators, with the building owner or developer as economic end-user and the architect/general contractor as specifier. The report notes the company holds ample raw-material inventory as a hedge against Middle East supply disruption. ### Customer types and end-markets **Design offices / architects:** specification of exterior and interior finishes. **General contractors and construction companies:** new-build commercial, public, logistics, data-centre and condominium projects. **Housing manufacturers:** detached houses. **Distributors / paint dealers:** primary channel. **Painting and installation contractors:** application; the key influencer in the renovation market. End-markets: (a) new construction (public works, private non-residential capex, housing), (b) renovation/repainting of the existing building stock (condominium large-scale repair cycles, detached-house repainting, factories/warehouses), and (c) fire protection of steel structures and insulation in non-residential buildings, notably logistics facilities, data centres, cold-chain warehouses and urban redevelopment. ### Independent characterization SK Kaken is best understood as a niche-dominant, high-share specialty formulator in a mature domestic market, more akin to a "category king" in textured architectural finishes than to a diversified paint major such as Kansai Paint or Nippon Paint. Its profitability (operating margin 11–12% vs. 8.4% at Kansai Paint and ~4% at Dai Nippon Toryo in FY2026) reflects specification-driven pricing power, an applicator ecosystem built over seven decades, and a product mix tilted toward premium renovation systems. Its weaknesses are structural: dependency on a shrinking/aging Japanese construction market, raw-material pass-through lags, and a balance sheet so over-capitalised (equity ratio ~85%) that ROE (7.2%) is held below the company's own 8% target and the shares trade below book value.

Revenue$0.7B
Employees2,404
Market CapN/A
Founded1955
Osaka, Japan
Siltech

Siltech Corporation

Premium
Information Technology

Siltech Corporation is a privately held, family-owned Canadian specialty chemicals manufacturer. It focuses on organo-functional (organo-modified) silicones: hybrid polymers made by grafting organic functional groups onto a siloxane backbone. Siltech does not compete in commodity silicone fluids or basic siloxane production, which are dominated by integrated majors such as Dow, Wacker and Shin-Etsu. Instead it occupies a downstream, high-mix, customization-led niche. It buys silicone intermediates and converts them into more than a hundred named derivative grades across brands such as Silsurf®, Silube®, Silwax®, Silquat®, Silmer® and Silstab®. Personal care is its most visible market. Industrial demand from polyurethane foam, inks and coatings, agriculture, pulp and paper, leather, oil and gas and car care gives it a diversified base. Its 2025 commissioning of a third plant in Fort Erie, Ontario (US$75M+) is its largest capital commitment to date and signals a shift from niche specialist toward scaled specialty producer. --- ### What the company does Siltech develops, manufactures and markets organo-functional silicone compounds and related specialties. The company describes these as built for specific customer applications using both patented and proprietary technology (company profile text reproduced on A-Leads). Its core chemistry has four steps: - Take silicone backbones (polydimethylsiloxanes, hydride-functional siloxanes, MQ/VQ resins). - React them with organic moieties: polyethers, alkyl chains, quaternary ammonium groups, amines, phosphates, carboxylates, fluorinated groups, esters, urethanes, and reactive groups such as acrylates and alkoxysilanes. - The result is "hybrid" materials that combine silicone attributes (low surface tension, spreadability, water repellency, softness) with organic attributes (water solubility, cationic substantivity, emulsification, reactivity, compatibility). - These are sold as performance additives used at low-to-moderate doses in customers' finished formulations. In a 2021 interview, Siltech's then global marketing and sales director Robert Ruckle described what the chemistry does in each market: - Personal care: formula stabilization, skin feel and conditioning. - Polyurethane foam: cell stabilization. - Pulp and paper: foam control and surface-tension modification. - Polymers: flexibility, haptics and impact resistance. - Coatings: flow and leveling, anti-cratering, slip and stabilization (Coatings World, 13 Apr 2021). ### Business model | Dimension | Characterization | Evidence | |---|---|---| | Revenue model | Almost entirely product sales (specialty chemicals sold by weight). No subscription or licensing revenue is disclosed. Toll or contract manufacturing is a secondary revenue stream: Siltech took on a long-term contract to keep making Rhodia's products after the 2010 plant purchase. | PCI Magazine, 31 Jan 2010 | | Commercial approach | Customization-led. Management has said much of the business was built customer-by-customer and project-by-project, and that it promotes new product launches less than peers, preferring co-developed custom solutions. | Coatings World, Apr 2021 | | Product vs. service mix | Product-dominated. Services such as custom silicone development, formulation support, application labs and technical data are bundled to win specifications and are not monetized separately (no disclosure). | GCI Magazine directory listing | | Go-to-market | More than 20 direct sales managers globally (2020), supplemented by a network of value-added distributors. Siltech LLC served as the designated US personal-care distributor until 2020. There is a European distribution centre in Rotterdam. | Cosmetics Business, Jan 2020; PU Europe | | Value chain position | Mid-stream converter/formulator. Upstream: silicone monomer/polymer producers and organic intermediate suppliers. Downstream: formulators of cosmetics, PU foam, coatings, agrochemicals and paper chemicals. | Independent characterization | | Revenue split (product/service/licensing) | ND | — | ### Customer types and end-markets | End-market | Typical Siltech function | Customer type | |---|---|---| | Personal care (hair, skin, colour cosmetics, sun care, cleansing) | Emulsifiers, conditioning agents, film formers, sensory modifiers, pigment dispersants | Global and indie beauty brands, contract manufacturers, ODM/OEM formulators | | Polyurethane foam | Cell-stabilizing silicone surfactants (Silstab® family) | Flexible/rigid foam producers, PUR/PIR insulation makers | | Inks, coatings and paints | Flow/leveling, slip, anti-cratering, hydrophobic film-forming emulsions | Paint and ink manufacturers; roof and concrete coatings | | Agriculture | Wetting/spreading adjuvants (silicone polyethers) | Agrochemical formulators | | Pulp and paper | Foam control, surface tension modification | Paper chemical suppliers | | Leather and textiles | Softness, protection (gum dispersions) | Leather finishers, textile processors | | Oil and gas | Defoamers, demulsification aids | Oilfield chemical companies | | Automotive / car care | Gloss, water repellency | Car-care formulators | | Plastics / polymer modification, 3D printing, composites | Flexibility, impact resistance, haptics; reactive silicones | Polymer compounders, resin formulators | The company's industry list covers 3D printing, agriculture, automotive, composites, household and industrial, inks and coatings, leather, mould release, oil and gas, personal care, polyurethane foam, and pulp and paper (company profile via A-Leads). Textiles and antifoam/defoamer applications appear in third-party profiles of Siltech LLC (GlobalData summary). ### Company's own description vs. independent characterization **Company's own framing:** Siltech presents itself as a specialist in developing and manufacturing organo-functional silicones. It stresses fast customization, partnership on strategic customer projects, and production at its own Ontario facilities (Cosmetics Business company profile, 31 Mar 2025). There is no annual report, so this framing comes from corporate profile text and press releases. **Independent characterization:** Siltech is best understood as a specialty silicone derivatives "job-shop at scale". Its moat is breadth of chemistry (more than 100 cosmetic grades are listed on SpecialChem alone), responsiveness and willingness to run small custom batches that larger players de-prioritize. Its main structural exposure is that it does not produce its own silicone base polymers. That leaves it buying feedstock from the same integrated majors it competes against downstream, which compresses margins when siloxane prices spike. The 2023–2025 Fort Erie build is therefore significant. It adds "semi-continuous" processing and capacity reportedly sufficient to roughly double nameplate output (Happi, NYSCC Suppliers' Day 2023 coverage). That pushes Siltech toward lower unit costs and a larger addressable volume.

RevenueN/A
Employees166
Market CapN/A
Founded1990
Toronto, Canada
SI

SI Group, Inc.

Premium
Information Technology

SI Group is a mid-sized, private, global maker of performance additives and chemical intermediates. Its core is antioxidant and stabilizer chemistry: phenolic, aminic and phosphite antioxidants, UV stabilizers and coupling agents. It is backward-integrated into alkylphenols and alkylated cresols. The company also has a long-established franchise in phenolic resins for tires and rubber (tackifying, reinforcing, bonding and curing resins), resins and intermediates for oilfield production chemistry, and specialty intermediates such as 4,4'-biphenol. The current company was formed in 2018 by combining legacy SI Group (Schenectady) with SK Capital's Addivant (the former Chemtura antioxidants business). Its stated vision is to become "the global performance additives powerhouse". Since 2021 it has divested non-core resins, closed high-cost Asian plants, exited ibuprofen and gone through two balance-sheet restructurings (2024 and 2025). After cutting net debt by about USD 1.7B in December 2025, it is now trying to return to growth through regional partnerships (Azelis, Dingjide, Shengxiao), new innovation centres and pricing actions. --- **Company's own description.** SI Group describes itself as a global leader in performance additives, process solutions and chemical intermediates (2026 boilerplate). Its chemistries improve the quality and performance of industrial and consumer goods in plastics, rubber and adhesives, fuels, lubricants, coatings and oilfield. Before 2026 the boilerplate also named "pharmaceuticals" and "active pharmaceutical ingredients". That wording disappears from 2026 releases, though it remains in the website metadata. Read together, this suggests the company is de-emphasizing APIs after it ended ibuprofen production in 2024. [siigroup.com/about; PRs Dec 2025 vs Mar–Jul 2026] **Five "Key Strategic Markets" (the company's own organizing framework)** [siigroup.com/about, 2026]: 1. **Core Solutions:** chemical intermediates for industrial uses and other end markets. 2. **Fuel, Lubricants & Coatings:** antioxidants, intermediates and specialty additives for coatings, fuels, greases and lubricants. 3. **Oilfield:** resins and intermediates for oilfield production chemistry. 4. **Plastics:** antioxidants, non-dust blends and additives for plastics stabilization, compounding and circularity. 5. **Rubber & Adhesives:** resins and additives for tires, technical rubber goods and adhesives. **Business model.** This is an almost entirely product-based model. SI Group manufactures and sells chemicals on volume contracts and spot orders, directly to large accounts and through distributors in other regions (Brenntag in EMEA since 2005; Azelis added for EMEA plastics additives from 1 January 2026). Service revenue (technical service, application development at six innovation centres) is bundled into product pricing and not monetized separately. No subscription or licensing revenue is disclosed. Two exceptions involve technology deals: in 2021 SI Group licensed industrial-resins technology to ASK Chemicals, and in 2026 it contributed proprietary biphenol technology to the Shengnova JV. Toll and co-production arrangements, such as the one with Dingjide in China, are increasingly part of the supply model. [Company PRs 2021, 2024, 2025, 2026] **Revenue model mix (estimate of character, not disclosed numerically).** **Value-chain position.** SI Group is a mid-stream specialty producer. It buys petrochemical building blocks (phenol, isobutylene and other olefins, cresols, phosphorus chemicals, amines). It converts them into alkylphenol intermediates, then into higher-value antioxidants and resins, which it sells to compounders, polymer producers, tire makers, lubricant and fuel additive blenders, and oilfield service and chemical formulators. The 2018 SK Capital rationale described the combined company as backward-integrated into key chemical intermediates. [SK Capital PR, 15 Oct 2018] **Customer types.** Customers include polyolefin and engineering-polymer producers and compounders; tire and technical-rubber manufacturers; adhesive formulators; lubricant, grease and fuel-additive companies; oilfield chemical formulators; coatings producers; and, historically, pharmaceutical formulators (ibuprofen, propofol). **End-markets served.** The website lists agriculture, automotive, building and construction, chemical intermediates, coatings, consumer goods, elastomers, electronics, fuel additives, furniture, grease additives, health and nutrition, lubricant additives, metal processing, oil and gas, oilfield chemicals, packaging, personal care, recycling, textiles, and tire and rubber. [siigroup.com navigation, 2026] **Independent characterization.** SI Group is a sub-scale but well-franchised antioxidant and stabilizer house. Its competitors are far larger (BASF, Songwon, Adeka) or low-cost Chinese producers (e.g., Rianlon). Its differentiation rests on four things: (i) integration into alkylphenols, where it claims market leadership; (ii) legacy brands from Addivant/Chemtura (NAUGARD, ANOX, LOWINOX, WESTON) and Albemarle (ETHANOX); (iii) a strong niche in tire phenolic resins; and (iv) niche specialty molecules (4,4'-biphenol). Since 2018, the investment case has been dominated by the leverage taken on in the SK Capital buyout. The 2024 and 2025 restructurings imply that operating cash flow could not service that debt during the 2023–2025 chemicals downturn.

RevenueN/A
Employees1,500
Market CapN/A
Founded1906
NY in, US
Shofu

Shofu Inc.

Premium
Information Technology

SHOFU is Japan's oldest and one of its most diversified dental consumables manufacturers, tracing its roots to the country's first high-quality porcelain artificial teeth in 1922. The company spans the full restorative workflow — artificial teeth, abrasives and polishing systems, composite resins, adhesives, cements, ceramics, CAD/CAM blocks and discs, and clinical equipment such as intraoral photography cameras — serving dental clinics and dental laboratories through dealers in Japan and wholly owned sales subsidiaries in the US, Germany, the UK, China, Singapore, India, Brazil and, since 2026, the Middle East. Its signature intellectual property is Giomer/S-PRG bioactive filler technology, embedded in the BEAUTIFIL composite family. With a debt-free balance sheet, an equity ratio above 80%, and overseas sales near 59% of revenue, SHOFU is a mid-cap niche consolidator that has set itself a ¥50bn sales target for FY2028 and an aspirational ¥250bn, 20%-margin "global top-10" goal for 2040. --- ### Company's own description The Yuho FY2026 describes the group as comprising SHOFU INC., 18 consolidated subsidiaries, one unconsolidated subsidiary, one equity-method affiliate (Sun Medical Co., Ltd.) and one "other affiliated company" (Mitsui Chemicals). The group operates as a comprehensive manufacturer of dental materials and equipment, with two smaller adjacent businesses: nail-care products and industrial abrasives. The Yuho identifies the main dental product families as artificial teeth, abrasives (grinding and polishing), dental metals, chemical products (restoratives, adhesives, CAD/CAM materials), cements, and machinery and instruments. The corporate philosophy is to contribute to global dental care through creative corporate activity. The corporate message used in investor materials translates as "supporting the ability to chew, smile and live." ### Business model and revenue model | Revenue type | Share of revenue | Comment | |---|---|---| | Product sales (consumables) | Large majority (precise split n.d.) | Restoratives, abrasives, artificial teeth, cements, CAD/CAM materials | | Product sales (equipment) | Minor share (n.d.) | Intraoral cameras, laboratory equipment, curing devices | | Repair / after-sales service | Minor (n.d.) | Equipment repair services; order backlog ¥494m at FY2026 end, all dental | | Subscription / licensing | Not material | CAD software "Go2 dental" is updated periodically; licensing revenue not separately disclosed | SHOFU runs a vertically integrated, product-sale business model. It does R&D in Kyoto (and at subsidiaries in Germany and the UK), manufactures in Japan (Kyoto, Shiga, Kumiyama), China (Shanghai, Changzhou), Vietnam, Germany and the UK, and sells primarily through dental dealers (domestically and in most export markets), supported by its own sales subsidiaries and a "academic network" of key opinion leaders. Revenue recognition is at delivery to customers (domestic sales recognised at shipment under the alternative treatment; exports recognised at shipment/loading under trade terms), per the Yuho FY2026 accounting policies. No single customer exceeds 10% of consolidated sales. ### Value-chain position SHOFU sits in the manufacturer tier of the dental value chain. It sources chemical and ceramic raw materials, adds value through proprietary filler chemistry, ceramics processing and precision abrasive manufacture, and relies on distributors (dental dealers) to reach end users. In Japan it is also a key supplier into the national health insurance-reimbursed restorative market, notably CAD/CAM crowns made from resin-based blocks and PEEK. ### Customer types and end-markets **Dental clinics (chairside):** composites (BEAUTIFIL), adhesives (BeautiBond), cements, polishing systems, preventive products, orthodontic materials, intraoral cameras. **Dental laboratories (labside):** artificial teeth, porcelain and stains (Vintage line), indirect composites (Ceramage), CAD/CAM blocks and discs, laboratory abrasives. **Dental dealers:** primary channel in Japan, North America and Europe. **Nail salons and consumers:** gel and acrylic nail systems (Nail Labo). **Industrial users:** rubber-bonded abrasives for moulds, ceramics and plastics (SHOFU Products Kyoto). ### Independent characterisation SHOFU is best understood as a restorative-materials specialist with a strong legacy franchise in prosthetics (artificial teeth, abrasives) that is pivoting toward digital dentistry (CAD/CAM materials, software, intraoral imaging) and overseas growth. Its competitive edge is chemistry-led differentiation (Giomer/S-PRG bioactive fillers) rather than scale. The economics show high gross margins (~59%) but SG&A-heavy cost structures (~46% of sales), typical of a mid-sized dental consumables player that must maintain dealer support, clinical education and multi-country regulatory compliance without the scale advantages of Dentsply Sirona or Envista. The Mitsui Chemicals capital tie-up (20.11%) gives SHOFU a strategic anchor shareholder that also owns competitor-cum-partner businesses (Kulzer and Sun Medical).

Revenue$0.3B
Employees1,462
Market CapN/A
Founded1922
Kyoto, Japan
Shandong

Shandong Ruifeng Chemical Co., Ltd.

Premium
Information Technology

Two similarly named listed companies should not be confused with it. 瑞丰新材 (300910.SZ), Xinxiang Richful Lube Additive, makes lubricant additives. 瑞丰转债 (123126) is this company's own convertible bond, which has now been redeemed. Shandong Ruifeng is one of China's leading producers of PVC processing and impact-modifying additives. It has about 200,000 t/yr of combined capacity across ACR acrylic processing aids and impact modifiers, MBS impact modifiers and MC impact modifiers. The company describes itself as the leader in domestic ACR and MBS, supplying close to 3,000 domestic customers and exporting to more than 60 countries under the "LUSHAN" brand. Earnings are thin and cyclical: net margin was 1.1%–5.0% over FY2021–FY2025, because the business is exposed to acrylate, butadiene and styrene costs and to PVC demand tied to construction. Management is reshaping the company into a broader "new materials" platform: - higher-margin engineering-plastic additives and core-shell rubber (CSR) tougheners aimed at replacing imports; - a 60 kt/yr PBAT biodegradables line being retrofitted for PETG/PCTG specialty polyester; - early-stage black phosphorus anode material, SBR battery binder and dextran; - since September 2026, a proposed CNY 499M controlling acquisition of loss-making electronic-resin maker Anhui Mituo, which would take it into copper-clad laminate (CCL) materials. H1 2026 profits rose sharply year on year, and the share price has nearly doubled in 2026. --- ### Company's own description In its FY2024 annual report summary, the company describes its core business as plastic additives in two lines. **General-purpose plastic (PVC) additives:** The main products are ACR processing aids and impact modifiers, MBS impact modifiers and MC impact modifiers, with combined capacity of nearly 200,000 tonnes. Each product family has its own end uses: - ACR goes into PVC pipes, profiles, WPC and SPC flooring, wall panels, transparent sheet and foam board. - MBS goes into transparent PVC sheet (pharmaceutical and consumer packaging), pipes, magnetic-card materials and functional films. - MC goes into wire and cable, hoses, tapes, rubber sheet and PVC profile/pipe modification. **Engineering-plastic additives:** The main products are PC/ABS toughening modifiers, ABS high-rubber powder and ASA rubber powder. The company states that domestic supply of these grades has historically been imported, mainly from Kaneka (Japan), Dow (US) and LG (Korea), and that its products have reached volume sales. The same report says the company has 60,000 t/yr of PBAT biodegradable polymer capacity. In a June 2025 institutional site-visit record, management organised the business into four segments: plastic-additive materials, polyester materials, new-energy materials and synthetic-biology materials. Tianfeng Securities (July 2026) describes the structure as "PVC additives + engineering-plastic additives + synthetic-biology materials + new materials". MarketScreener's summary of the filings describes three businesses: plastic additives; biodegradable materials (PBAT); and a "new product" business covering special polyester, synthetic biomaterials, battery binders and black phosphorus. ### Independent characterisation Ruifeng is best understood as a mid-cap commodity-to-specialty intermediate chemical producer. More than 90% of revenue still comes from a single mature product family, PVC additives. Revenue is almost entirely product sales: tonnage-based, priced off raw-material costs, and with no meaningful service, subscription or licensing income. S&P data show "other revenue" of only CNY 2–7M a year. **Value-chain position.** Ruifeng buys monomers and polymers, including methyl acrylate, butyl acrylate, butadiene, styrene and HDPE, and polymerises them into core-shell or chlorinated polymer additives. Compounders and converters use these at 1–10 phr loadings in PVC and engineering-plastic processing. The additive is a small share of the customer's bill of materials but critical to performance, such as impact strength, melt processing and transparency. That gives Ruifeng moderate pricing power in normal markets. Tianfeng notes the company reprices flexibly in line with raw materials, but price competition intensifies in downturns: management cut prices in Q1 2025 to defend market share. **Customer types.** PVC pipe, profile, flooring and sheet extruders (heavily tied to construction and real estate); packaging film and pharmaceutical blister-sheet producers; card makers; ABS/ASA and PC/ABS compounders serving automotive and electronics; and, in development, lithium-ion battery cell makers (SBR binder) and CCL laminators (CSR, and electronic resins through the Mituo deal). **End-market exposure.** Construction and building materials are the largest exposure through PVC pipes, profiles and flooring. Packaging, consumer goods, automotive, electrical/electronics, agriculture and disposable packaging (PBAT mulch films and bags), and new energy and electronics (developing) make up the rest. Management has said it is deliberately shifting PVC-additive sales toward non-property uses such as sheet, cards, packaging film and pharmaceutical packaging to offset the property cycle (H1 2026 commentary). **Revenue model mix.** About 100% product sales. Service, subscription and licensing revenue are not publicly disclosed and are assessed as immaterial.

Revenue$0.3B
Employees905
Market CapN/A
Founded1994
Shandong, China
Septodont

Septodont Holding

Premium
Information Technology

**Listing status vs. input list:** The input list classifies the company as a "Public company". This is incorrect. Septodont Holding is unlisted and privately held. Its capital is wholly owned by the Schiller family: the former CEO and current Chairman Olivier Schiller, his father Henri Schiller, and his five children. Septodont is the world's largest maker of dental local anesthetics and a family-controlled specialist in pharmaceutical dentistry. Its core franchise is injectable anesthetic cartridges. The group produces about 500 million per year, which management characterizes as roughly 20 cartridges injected every second worldwide, and historically more than half of global production. Around that core, Septodont has built adjacent businesses: needles and injection devices, topical anesthetics, reversal agents, bioactive restorative and endodontic materials based on its proprietary Active BioSilicate Technology (Biodentine, BioRoot RCS, BioRoot Flow), and surgical biomaterials. A third leg is sterile-injectable contract manufacturing (CDMO) through Novocol Pharma in Canada, which counts Moderna as an anchor client. The group has grown from EUR 199M (2014) to EUR 443M (2024), an 8.3% CAGR, financed with bank debt rather than outside equity. The 2024 Inibsa acquisition lifts it toward ~EUR 560M. Management's stated ambition is EUR 1bn of revenue by the 2032 centenary. --- ### What the company does Septodont develops, manufactures and distributes dental pharmaceuticals and medical devices. The Chairman's January 2025 description of the group's production scope covers: - injectable anesthetics; - topical anesthetics (applied locally without injection); - needles; - anesthetic reversal agents ("neutraliseurs d'anesthésique"); - safety injection devices and syringes. Beyond pain control, the company is active in: **endodontics:** root canal sealers and obturation materials, with files now added through a partnership; **restorative dentistry:** dentine substitutes; **surgical dentistry:** hemostatics, alveolar dressings and synthetic membranes; **infection control:** and related consumables. ### Company's own description Company boilerplate (Indeed / corporate profile) describes Septodont as enhancing lives through innovative, safe and effective healthcare solutions. It positions the company at the forefront of pharmaceutical dentistry since the Schiller family founded it in 1932, as still family-owned, and as the world leader in dental pain management. No statutory annual report is published, so no annual-report description is available. ### Business model and revenue model | Revenue stream | Nature | Disclosure status | |---|---|---| | Dental pain management (anesthetic cartridges, topicals, needles, syringes, reversal agents) | Product sales of consumables, recurring and volume-driven | Share of revenue not publicly disclosed. The Chairman notes pain control is only ~5% of a dentist's consumables spend, which bounds the addressable market | | Dental biomaterials, restorative, endodontic and surgical products | Product sales of consumables | Not publicly disclosed | | CDMO (Novocol Pharma, Canada): aseptic fill-finish, labelling and packaging for third parties | Contract manufacturing services, long-term supply agreements | Not publicly disclosed | | Licensing / subscription | No material licensing or subscription revenue identified | n/a | The model is overwhelmingly a product model: high-volume regulated consumables sold mainly through dental distributors and dealers, plus subsidiaries in key markets. A smaller but strategic service model comes from CDMO. Distribution is via subsidiaries or distributor networks in about 110 countries (Chairman, 2025). Older corporate boilerplate cites 150+ countries; the difference likely reflects a change in definition, from countries supplied to countries with active presence. Septodont sells worldwide except North Korea, Venezuela and Iran (Chairman, 2025). ### Value-chain position Septodont is vertically integrated: **R&D and regulatory:** R&D centres in France and Canada, and product registrations in many jurisdictions (e.g., a first-in-40-years anesthetic registration in Japan). **Active-ingredient formulation and sterile manufacturing:** automated washing, filling and terminal sterilization of cartridges. **Component manufacturing:** needles and injection devices at Mazamet/Aussillon, France. **Commercialization:** country subsidiaries and dealers. It outsources selectively. For example, Ultracain cartridges acquired from Sanofi continue to be manufactured by Sanofi in Frankfurt under contract (ZWP Online, March 2022). ### Customer types and end-markets - General dental practitioners and specialists (endodontists, oral surgeons, pediatric dentists), reached mainly through dental distributors and DSOs. The group has a "Global VP, Corporate Accounts" role, implying a key-account and DSO channel. - Hospitals and dental schools. - Pharmaceutical and biotech companies, as CDMO clients (Moderna). - Government health systems and tenders (implied by registrations in many national markets). ### Independent characterization Septodont is a classic French "ETI" (mid-sized company) "hidden champion": a dominant share in a narrow, highly regulated, low-ticket but indispensable consumable, protected by regulatory barriers and sterile-manufacturing know-how. Its strategic challenge, stated openly by the Chairman, is growth beyond a niche it already leads. Management is addressing this along three lines: 1. adjacency expansion within dentistry (biomaterials, endodontics); 2. sterile-injectable CDMO; 3. consolidation by acquisition (Sanofi dental brands, Inibsa). The model is cash-generative, and the group has used leverage (capped at 3.5x EBITDA) rather than equity. That preserves family control but concentrates financial risk.

Revenue$0.5B
Employees1,359
Market CapN/A
Founded1932
Saint-Maur-des-Fossés, France
SePRO

SePRO Corporation

Premium
Information Technology

| Field | Detail | Source / Date | |---|---|---| | Legal name | SePRO Corporation. Copyright notices on the 2026 website read "SEPRO Corporation". | seproscientific.com footer, 2026 | | Trading / brand name | SEPRO Scientific™ (brand refresh announced 7 Jul 2026) | Business Wire, 7 Jul 2026 | | Former names / brands | SePRO Corporation (1994–2026). Divisional brands: SePRO Aquatics, SePRO T&O, EutroPHIX, SePRO Digital. Now SEPRO Water and SEPRO Land. | Company releases 2020–2026 | | Founded | 1994 | Company "About Us"; EPA registration records 1994 | | Founder | William ("Bill") H. Culpepper | NC State CALS board bio; company releases | | Incorporation jurisdiction | Not publicly disclosed. Registrant address is Indiana; the state of incorporation is not stated in the reviewed sources. | n/d | | Headquarters | 11550 North Meridian Street (Suite 200 on historic EPA filings), Carmel, Indiana 46032, USA | EPA PPLS records 1994; CB Insights; LeadIQ | | Primary R&D / operations site | SePRO Research & Technology Campus (SRTC), 410 acres, Whitakers, North Carolina | Company "About Us"; Lawn & Landscape (2004) | | Stock exchange / ticker | None. Not listed. | n/a | | ISIN / CUSIP | None (no listed securities) | n/a | | EPA company/registrant number | 67690 (e.g., EPA Reg. 67690-4 Sonar A.S.; 67690-6 Sonar Technical) | EPA PPLS label records, 1994 | | Fiscal year end | Not publicly disclosed | n/d | | Auditor | Not publicly disclosed | n/d | | Ownership | Majority: Stanley Capital Partners (SCP), since July 2024. Minority co-investor: Goldman Sachs Alternatives. Prior sponsor Excellere Partners (2019–2024) exited. | SePRO release 29 Jul 2024; Sidley Austin; S&P Global Deal Wrap | | Market capitalization | Not applicable (private). 2024 transaction enterprise value not publicly disclosed. | n/d | | Employees (latest) | ~131 (PitchBook, 2025); ~142 (LeadIQ, May 2026); ~147 (BuiltIn); "165+ scientists & professionals" (company website, 2026) | See 1.3 | | Website | www.seproscientific.com (new); legacy www.sepro.com / advantage.sepro.com; digital login auth.seprodigital.com | Company websites | | CEO | Tyler Koschnick, Ph.D., President & CEO | seproscientific.com/leadership | | Industry codes (third-party) | SIC 2879-family (agricultural chemicals) per ZoomInfo; PitchBook primary industry "Agricultural Chemicals" | ZoomInfo; PitchBook | | Metric | 2004 | 2025 | 2026 | |---|---|---|---| | Employees, third-party or press count (persons) | 65 | 131 | 142 | | Employees, company-stated "scientists & professionals" (persons) | — | — | 165 | *Sources: 2004 figure from Lawn & Landscape's report on the SRTC purchase. 2025 from PitchBook ("131 as of 2025"). 2026 from LeadIQ (May 2026). The 165 figure is the company's own 2026 website claim ("165+"); it likely includes acquired teams (Arietta.ai, Resolve Hydro, Green Eyes, ESL) and possibly contractors.* A clean 3-year trend from a consistent source is not available. The direction is clearly upward, driven by four acquisitions between April 2025 and April 2026. These were partly offset by the transfer of several agriculture-team staff to Gowan in November 2025. SEPRO Scientific is a private-equity-backed US specialty environmental-solutions company. It has spent three decades building the leading franchise in North American aquatic plant and algae management. Its anchor brands are Sonar® (fluridone), ProcellaCOR® (florpyrauxifen-benzyl), Galleon® (penoxsulam), the Applied Biochemists® copper algaecide range, and now EarthTec®. Since 2024, under Stanley Capital Partners and Goldman Sachs Alternatives, management has been repositioning the company from a niche registrant-and-marketer of pesticides into a "science-led, digital-first" water-health platform. The new model spans monitoring (satellite and AI via AIM™, NuLAB nutrient sensors), diagnostics (an in-house lab), restoration (treatment chemistry, EutroPHIX phosphorus programs), and long-term stewardship through its "Stewards of Water" applicator network. A smaller SEPRO Land division sells plant growth regulators, fungicides, insecticides and herbicides to golf, landscape and ornamental growers. The strategic bet is that integrated data plus chemistry creates stickier, higher-value customer relationships than product sales alone. --- ### The company's own description SePRO publishes no annual report. Its official self-descriptions have shifted materially over the past seven years, and the sequence is itself analytically useful. **Legacy "About Us" (pre-2024):** SePRO described itself as dedicated to discovering and developing sustainable solutions. Its mission was to provide plant protection and plant management products for specialized markets, by acquiring, developing, manufacturing and marketing value-added products. It also cited partnerships with major agricultural chemical companies to adapt their chemistries to SePRO's markets, with the 410-acre SRTC at the centre of product innovation. **2020–2024 framing:** "aquatics industry leader" and "specialty environmental restoration company" (2020 Applied Biochemists release; 2024 Stanley Capital release). **2025 framing:** "a leader in environmental solutions for water and land restoration," pursuing transformation into a "technology-enabled environmental health company" (Koschnick, Arietta.ai release, Aug 2025). **2026 framing (current):** SEPRO Scientific calls itself a science-led environmental solutions company that protects, preserves and restores water and land ecosystems. It delivers integrated solutions across monitoring, diagnostics, restoration and long-term stewardship (Business Wire boilerplate, Jul 2026). ### Independent characterization SePRO is best understood as a niche "registrant-marketer-steward" in specialty pesticides. Historically it did not discover active ingredients. In a 2004 interview, founder Bill Culpepper stated plainly that the company does not do discovery or find new molecules. Instead it: 1. **In-licenses or acquires molecules and registrations** from large agrochemical originators. Examples: fluridone from DowElanco in 1994; ProcellaCOR's active, florpyrauxifen-benzyl, originates from Dow AgroSciences/Corteva's Rinskor™ chemistry; penoxsulam in Galleon is likewise of Dow origin. The Griffin/DuPont TNO&A portfolio was acquired c. 2004, and the Applied Biochemists copper portfolio in 2020. 2. **Generates the niche-specific data package** (aquatic, turf, ornamental) at the SRTC and with university and agency partners, then secures EPA and state registrations. 3. **Formulates, packages and distributes** in-house from the SRTC. These activities were brought in-house after the 2004 campus purchase. 4. **Sells through distribution** to professional applicators, lake management companies, golf superintendents, landscapers, nurseries and greenhouses, utilities, irrigation districts and public agencies. 5. **Wraps products in technical stewardship.** Technical Specialists write treatment prescriptions, and the Stewards of Water network certifies applicators (about 160 accredited applicator companies as of 2011). The 2024–2026 pivot adds a data-and-services layer on top of this model: **AIM™:** satellite and AI water monitoring, from the Arietta.ai and Resolve Hydro acquisitions. **NuLAB:** real-time nutrient analyzers, from Green Eyes. **Water Diagnostics laboratory:** 40+ assessments, with most results in under 72 hours. **EutroPHIX:** a phosphorus/HAB restoration division launched in 2020. The intended effect is to move the company up the value chain from product vendor to outcome-based water-health partner. ### Revenue model mix (qualitative; no disclosed split) | Revenue stream | Description | Est. relative importance | Disclosure status | |---|---|---|---| | Product sales: Water | Aquatic herbicides, algaecides, molluscicides, dyes, water-quality products (64 SKUs listed under SEPRO Water, 2026) | Dominant (analyst judgment) | Revenue n/d | | Product sales: Land | PGRs, fungicides, insecticides/miticides, herbicides for golf, landscape, ornamental (31 SKUs listed, 2026) | Secondary (analyst judgment) | Revenue n/d | | Product sales: Specialty agriculture | Brake®/Brake On! herbicides, Bio-Tam® (US marketing transferred to Gowan, Nov 2025) | Declining / exited as direct business | n/d | | Services | EutroPHIX restoration programs; Lab/Water Diagnostics; technical prescriptions | Small but strategic | n/d | | Digital / subscription | AIM™ monitoring platform (log-in portal at seprodigital.com); pricing not published | Nascent | n/d | | Equipment | NuLAB nutrient analyzers, monitoring equipment (Green Eyes) | Nascent | n/d | | Licensing income | Royalty or licence income likely under the Gowan agreement for Brake® (structure not disclosed) | Minor | n/d | | Consumer / DIY | diy.sepro.com consumer pond products | Minor | n/d | ### Value-chain position Upstream, active ingredients are sourced or licensed from originators and toll manufacturers (supplier identities n/d). SePRO occupies the middle of the chain: registration, formulation, packaging and technical marketing. Downstream, products move through distributors to professional applicators, who serve end owners such as HOAs, municipalities, utilities, golf clubs and growers. The 2025–2026 digital acquisitions push SePRO toward the end owner. AIM™ explicitly targets water professionals, authorities and water caretakers, the last group via participating Stewards of Water. The architecture deliberately routes end-owner demand back through SePRO's applicator channel rather than bypassing it. ### Customer types and end markets | End market | Customer types | Example offerings | |---|---|---| | Lakes & ponds (recreational, residential, HOA) | Lake & pond management companies, HOAs, lake associations, homeowners | Sonar®, ProcellaCOR®, Galleon®, Captain XTR, Cutrine®-Plus, Aquashade®, AIM™ | | Drinking-water reservoirs & utilities | Municipal water authorities, water districts | EarthTec®, EarthTec® QZ (NSF/ANSI 60), Phoslock® (historic distribution), diagnostics | | Canals & irrigation conveyance | Irrigation districts, agricultural water suppliers | Galleon® SC, Natrix® CA, EarthTec®, AgriTec® | | Public agencies (invasive species) | State natural-resource agencies, US Army Corps-type programs, watershed districts | ProcellaCOR®, Sonar® (hydrilla, Eurasian watermilfoil programs) | | Golf | Superintendents | Cutless®, Legacy®, Musketeer®, Obtego®, Junction®, StriCore® | | Lawn & landscape | Landscape contractors, lawn care operators, grounds managers | Legacy®, Cutless® QuickStop™, Shrub & Tree Sculptor™, Octane®, StriCore® | | Ornamental (greenhouse/nursery) | Greenhouse and nursery growers | Topflor®, A-Rest®, Hachi-Hachi® SC, Akari®, Decree®, Barracuda®, BattleLine® | | Specialty agriculture (legacy) | Cotton and specialty crop growers | Brake®, Brake® On!, Bio-Tam® (transferred to Gowan 2025) | | Canada | Aquatic managers | ProcellaCOR® FX (marketed as "Canada's newest tool") |

RevenueN/A
Employees142
Market CapN/A
Founded1994
Indiana, US
Sanitized

Sanitized AG

Premium
Information Technology

SANITIZED AG is a Burgdorf-based, family-owned Swiss specialty chemicals company that has developed antimicrobial hygiene functions and material-protection additives since 1935. It sells additives — not finished goods — to textile mills, polymer processors and paint/coatings manufacturers, and monetizes them through a combination of chemical sales and the Sanitized® ingredient brand and quality seal, which roughly 520 companies used on their end products as of 2021. Its textile platforms (Odorex™ biocide-free odor neutralization, Puretec™ quat-silane antimicrobial finishes, Silvertec™ silver-based durable protection) are, since 1 February 2026, distributed worldwide exclusively by Germany's Rudolf Group, ending a textile go-to-market relationship that traced back to Sandoz's textile division in 1989 and later Clariant and Archroma. Polymer additives and paint/coatings preservation are sold via regional distributors such as Bodo Möller Chemie. Sanitized is a niche, regulatory-intensive player whose moat rests on registered actives, application know-how and brand licensing rather than scale. --- ### What the company does SANITIZED AG develops, formulates, registers and markets antimicrobial and odor-management additives that are incorporated into textiles, plastics (polymers) and paints/coatings during the customer's manufacturing process. Its stated functional categories, per its German-language company profile on CHEManager, include antibacterial products, anti-mold products, active ingredients against material degradation, products against house dust mites, and in-can and dry-film preservation for architectural paints. The company describes its Sanitized® name as simultaneously a brand name and a quality seal used to label finished textile and plastic products. The commercial register states the company's purpose as the development, manufacture and sale of chemical products of all kinds, in particular those used under the Sanitized process for antimicrobial finishing or preservation of materials such as plastics, textiles and leather. ### Company's own description (latest available boilerplate) The company does not publish an annual report. Its most recent self-description, used in trade directories and partner material (e.g., Performance Days exhibitor list, October 2025), positions SANITIZED as the leading Swiss expert in antimicrobial and biocide-free odor-management solutions for textiles, preventing odor-causing bacteria from building up and delivering odor neutralization across applications from sportswear to workwear, working with brands and mills worldwide on customized solutions. Its longer-standing boilerplate describes it as a world-leading producer of natural odor-management, antimicrobial hygiene function and material protection for textiles and polymers, using only scientifically researched and registered active ingredients that have passed internationally approved risk assessments. ### Independent characterization Sanitized is best characterized as a formulator and ingredient brand owner occupying the specialty-additive layer of three value chains. Its economic engine has three parts: 1. **Additive sales** — formulated chemicals sold by weight to mills, compounders and paint makers (via distributors). 2. **Ingredient-brand licensing / co-marketing** — the Sanitized® seal and "Seal of Confidence" let downstream brands differentiate finished goods; the company explicitly bundles technology guidance, marketing support and regulatory support as part of its offer. 3. **Regulatory asset ownership** — registrations under the EU Biocidal Products Regulation (BPR) and US EPA FIFRA are costly barriers that small competitors struggle to replicate; Sanitized states products such as Puretec™ and Silvertec™ are EPA FIFRA-registered and EU BPR-compliant. ### Revenue model mix | Revenue stream | Description | Disclosed share | |---|---|---| | Product sales (additives) | Textile finishes, polymer masterbatch/additives, paint preservatives | Not publicly disclosed (believed dominant) | | Brand licensing / marketing services | Sanitized® ingredient brand and quality seal for end products | Not publicly disclosed | | Technical / testing services | Application testing and microbiology testing at Burgdorf TecCenter | Not publicly disclosed (likely bundled) | | Subscription | None identified | — | ### Value-chain position Upstream: active-substance producers (e.g., zinc pyrithione, silver/glass-ceramic carriers, quaternary silanes) → Sanitized (formulation, registration, branding) → distributors (Rudolf for textiles; Bodo Möller, Chemlogis, Ferro-Plast etc. for polymers/preservation) → textile mills / polymer processors / paint makers → consumer and industrial brands → end users. ### Customer types and end-markets | End-market | Typical applications | Evidence | |---|---|---| | Sportswear / activewear | Polyester odor control ("permastink") | Odoractiv 10 and Puretec releases | | Workwear | Odor neutralization | Performance Days profile; OX20 description | | Home textiles & bedding | Mattresses, bedding, dust-mite and bedbug protection | Interzum Guangzhou 2009 release | | Technical textiles / geotextiles | Material protection | TecCenter release 2016 | | Polymers — flooring, surfaces, kitchenware, artificial leather | Antimicrobial, anti-pink-stain, anti-biofilm | Bodo Möller and PL 14-32 releases | | Paints, coatings, adhesives, sealants (ACES) | In-can and dry-film preservation | Sanitized Preservation India release 2019; Bodo Möller 2023 | | Healthcare, food industry, kitchen & bath | Antimicrobial hygiene | Motherbase keyword profile |

RevenueN/A
Employees61
Market CapN/A
Founded1935
/Burgdorf, Switzerland
Rubamin

Rubamin Ltd.

Premium
Information Technology

Rubamin is a Vadodara-based, promoter-owned industrial group. It has reinvented itself from a four-decade-old zinc-chemicals and metal-intermediates manufacturer into what it calls India's largest zero-waste hydrometallurgical recycler of critical metals. The India business recovers zinc, molybdenum, vanadium, tungsten, cobalt, nickel, manganese, copper and, since 2025, lithium. Its feedstocks are galvanising dross and ash, spent hydroprocessing and residue catalysts from oil refineries, and end-of-life lithium-ion batteries. The output is high-purity metal chemicals, sold back into catalyst manufacturing, tyres, animal feed, fertilisers, pharmaceuticals, personal care and battery supply chains. Operations are anchored by a Green Recycling Complex at Halol, Gujarat, which the company now describes as roughly 90 acres. Alongside this, the group runs a separately profiled African business: copper blister smelting, copper minerals, drilling and services in the Democratic Republic of Congo, held through UAE and Congolese subsidiaries and joint ventures with state miner Gécamines. The group is conservatively financed (gearing ~0.22x, net cash) and rated AA- by CRISIL. Its growth narrative rests on battery recycling and residue-catalyst capacity commissioned in 2024–2025. --- ### What the company does Rubamin runs two economically distinct businesses under one consolidated group, as CRISIL describes in its July 2024 analytical approach: 1. **India business ("commodity waste recycling")** — Rubamin Private Limited and Indian subsidiaries (Kepler Resources Pvt Ltd, Rubamin Kepler Pvt Ltd). Hydrometallurgical and pyrometallurgical recycling of metal-bearing secondary materials into specialty metal chemicals. The company's website now organises this into three business lines: - **Zinc Recycling (ZYNK® brand)** — zinc oxide and other zinc compounds made from zinc dross and ash (secondary) and primary zinc. Combined capacity exceeds 50,000 TPA, with 30,000 TPA of dross/ash treatment capacity and 100+ customers globally. - **Catalyst Recycling** — full-cycle management of spent catalysts from oil refineries. Molybdenum, tungsten, vanadium, cobalt and nickel are recovered and sold largely back to catalyst manufacturers. Capacity covers 20,000 TPA of hydroprocessing spent catalyst plus an additional 35,000 MT residue (resid) spent-catalyst treatment facility. - **Battery Recycling** — lithium-ion battery (LIB) shredding (10,000 TPA, commissioned Q1 CY2025 at Halol) and black-mass refining (7,500 MTPA per the website timeline), producing cobalt, nickel, manganese, lithium and copper compounds and EPR (Extended Producer Responsibility) credits. 2. **Overseas business ("commodity-based products")** — Rubamin FZC (UAE, direct subsidiary) and DRC step-down subsidiaries (Rubamin SARL, Rubaco SARL, Minalex SARL, Codema SARL), plus proportionately consolidated joint ventures (Kaponda Mining Resources SAS, Lualaba Mining Resources SAS, Cotess SARL, Rubatek SARL). Activities include copper blister production, sale of copper minerals and ore, and services such as drilling, equipment rental and gas sales (CRISIL RR 2022–2024). The group entered the DRC in 2004 as a copper blister producer (GBR interview, Navin Dalmia). The company's broader self-description lists metal recycling, specialty chemicals, metal intermediates, mining, industrial gas production, mineral exploration and engineering services (website, "Who We Are"). ### Company's own description (paraphrased from website, 2026) Rubamin presents itself as a pioneer of critical-mineral recycling in India. Its pitch is that it treats as recyclable what others classify as hazardous industrial waste, and reclaims value from refinery catalysts, galvanising zinc waste and end-of-life EV batteries. It describes a cradle-to-cradle model and a "Power of Zero" decarbonisation agenda, under which non-renewable inputs and polluting outputs are progressively replaced. It also states that close to half the output of its spent-catalyst recycling is supplied to global catalyst manufacturers. ### Business model and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Revenue type | Overwhelmingly product sales (metal chemicals, intermediates, copper blister/minerals). Secondary revenue from services: tolling/recycling fees for catalyst and battery handling (implied by "full-cycle catalyst management"), EPR-credit facilitation, and DRC drilling/equipment rental/gas sales | Website; CRISIL RR 2024 | | Subscription / licensing | None disclosed | — | | Pricing mechanism | Formula-based pricing linked to metal benchmarks, inventory hedging, receivables insurance | CRISIL RR 2022/2023/2024 | | Customer concentration | Top 10 customers = 50–60% of revenue across FY2022–FY2024 | CRISIL RR 2024 | | Export intensity (India business) | ~50% (FY2022/FY2023) rising to 50–55% (FY2024). IndiaMART lists 60–80% export share (conflicting) | CRISIL RR; IndiaMART | | Working-capital intensity | Gross current assets of 150–210 days in the five years to FY2024; inventory 90–120 days; debtors 50–75 days | CRISIL RR 2024 | ### Value-chain position Rubamin sits at the secondary-raw-material processing and refining step of the metals value chain. On the input side it is a waste-management solution provider to refineries (spent catalysts), galvanisers (dross/ash), battery OEMs and gigafactories (production scrap) and EPR-obligated producers (end-of-life LIBs). On the output side it is a supplier of refined metal chemicals to catalyst makers, tyre/rubber compounders, feed/fertiliser formulators, pharmaceutical and cosmetic companies, and battery/precursor makers. This "two-sided" position, where it can be paid to take feedstock and paid again for product, underpins its historically higher margins in the India business (20.1% FY2023; 20.5% FY2024 per CRISIL) versus the overseas copper business (10.1% FY2023; 10.9% FY2024). ### Customer types and end-markets | End-market | Products supplied | Source | |---|---|---| | Tyre & rubber | Zinc oxide (activator) | CRISIL RR; Zonebourse; website | | Animal feed & veterinary | Feed-grade zinc oxide (FAMI-QS certified) | Website | | Fertilisers & crop protection | Zinc sulphate, zinc compounds, sodium/ammonium molybdate | Website; CRISIL | | Pharmaceuticals, supplements, food | IP/BP/USP-grade zinc oxide; WHO-GMP French-process unit | Website | | Cosmetics / personal care (sun care) | High-purity zinc oxide powders, dispersions | Website; Distil PR, Mar-2026 | | Refinery catalysts | Molybdenum, tungsten, vanadium, cobalt and nickel chemicals; zinc for desulphurisation catalysts | Website | | Paints, plastics, ceramics, glass, electronics, fire retardants | Zinc compounds | Website; Zonebourse | | Water treatment, biocides | Metal chemicals | Website | | Batteries / EV supply chain | Cobalt carbonate, cobalt hydroxide, cobalt sulphate, lithium carbonate (lithium hydroxide possible), nickel/manganese compounds | EVreporter interview | | Copper industry (DRC) | Copper blister, copper minerals | CRISIL RR | | EPR-obligated producers | EPR credits for LIB recycling | Website (EPR portal) | ### Independent characterisation Rubamin is best understood as a mid-cap, promoter-controlled specialty-metals recycler with a commodity-smelting appendage in Africa. Its India franchise has real moats: decades of hydrometallurgical know-how, a patented fluidised-bed roasting process, regulatory permits to handle hazardous waste, and multiple GMP/feed/food certifications. These support repeat, specification-driven customer relationships. The DRC business adds scale but also volatility and sovereign risk, illustrated by the FY2023 Gécamines pricing dispute. Group profitability therefore swings with copper, cobalt, molybdenum and zinc prices. The strategic bet now is to redeploy the balance sheet into battery-materials recycling and residue-catalyst treatment, shifting the mix toward structurally growing, policy-supported feedstocks.

RevenueN/A
Employees800
Market CapN/A
Founded1981
Vadodara, India
RNAissance

RNAissance Ag

Premium
Information Technology

RNAissance Ag is an early-stage US agricultural biotechnology company developing sprayable, RNA interference (RNAi)-based biopesticides. Spun out of the Donald Danforth Plant Science Center in St. Louis and incubated by venture developer TechAccel, it holds an exclusive license to RNAi technology discovered at the Danforth Center and designs double-stranded RNA (dsRNA) molecules that silence essential genes in a single target insect species, aiming to kill the pest while sparing pollinators, beneficial insects, animals and people. Its lead programs have targeted lepidopteran pests — notably diamondback moth and fall armyworm — with Colorado potato beetle among additional targets. Through its 2020 acquisition of RNAgri, it also owns a dsRNA manufacturing platform aimed at the low per-gram cost required for broad-acre spraying. The company is pre-commercial, pre-revenue as far as public sources show, and operates in a nascent category whose first sprayable product (a competitor's) was registered by the US EPA only in December 2023. --- ### What the company does RNAissance Ag develops topically applied (sprayable) RNAi insecticides. The scientific principle is that a dsRNA molecule, when ingested by an insect, is processed by the insect's own RNAi machinery into small interfering RNAs that suppress expression of a targeted essential gene, leading to feeding cessation and death. Because the sequence is matched to a specific gene in a specific species, the company's products are designed to be highly selective, non-toxic to non-target organisms, and biodegradable. Company releases (October 2022) state that its designs can also be used as pesticidal traits in crop seeds, i.e., expressed in-plant rather than sprayed. The company has two technology pillars: 1. **Target discovery and product design** — sequences licensed from the Danforth Center and the company's own discovery work, including (per the Danforth Center's 2019 IN2 profile) novel mechanisms to target lepidopteran pests across a range of crops, and a high-throughput screening platform to identify biological insecticides. 2. **dsRNA manufacturing** — the RNAgri platform acquired in June 2020, aimed at producing dsRNA at cost, yield and purity suitable for field application. ### Company's own description RNAissance Ag does not publish an annual report. Its most consistent self-description, repeated in the October 2022 CEO-appointment release, is that its primary focus is developing sprayable RNAi pesticides against pests such as diamondback moth, fall armyworm and several others, designed to be highly specific to the target pest, non-toxic to other organisms, and biodegradable, with additional applicability as seed traits. The 2019 IN2 cohort announcement described it as a biotechnology startup focused on delivering RNA-based insecticides for crop protection. ### Business model and revenue model | Dimension | Characterization | Basis | |---|---|---| | Stage | Pre-commercial R&D / development stage | No registered product or sales disclosed in any public source | | Revenue | Not publicly disclosed; no evidence of product revenue | PitchBook revenue field blank | | Likely model — products | Formulated biopesticide products sold through ag-retail/distribution channels once registered | Inferred from stated focus on sprayable products (analyst characterization) | | Likely model — licensing | Out-licensing of sequences/traits to seed and crop-protection majors (company states designs can serve as seed traits) | Oct 2022 release; analyst inference | | Likely model — services / manufacturing | Collaborative R&D, entomology efficacy testing, and potentially dsRNA supply | MTEC directory lists collaborative R&D partnerships and entomology testing/efficacy evaluation as services | | Non-dilutive funding | Grants/incubator support (Wells Fargo IN2: up to USD 250,000 plus technical support) | IN2 announcement, 2019 | Product vs. service vs. subscription vs. licensing revenue mix: not publicly disclosed. ### Value-chain position RNAissance sits at the discovery/development end of the crop-protection value chain: target identification → dsRNA design → manufacturing → formulation (with partners such as AgroSpheres) → regulatory registration (US EPA under FIFRA) → distribution to growers. It has internalized manufacturing (RNAgri) but has not been shown to own formulation, regulatory or distribution capabilities at scale. ### Customer types and end-markets | End-market | Target pests named | Crops implied | Status | |---|---|---|---| | Vegetables / brassicas | Diamondback moth (DBM) | Cabbage and other brassicas | Lead program; field trials planned summer 2020 | | Row crops / field crops | Fall armyworm (FAW) | Corn (maize), sorghum and others | Field trials planned summer 2020 | | Potatoes / solanaceous crops | Colorado potato beetle | Potato | Named as pipeline target (Dec 2022) | | Seed traits | Not specified | Not specified | Stated application, no disclosed program | Ultimate customers would be growers (via distributors/retailers) and potentially seed and crop-protection companies as licensees. ### Independent characterization RNAissance Ag is best understood as a small, regionally anchored (St. Louis/Kansas City) venture-development portfolio company whose public profile peaked in 2019–2022. Its technology thesis has been validated at the category level — the EPA's December 2023 registration of GreenLight Biosciences' Calantha (ledprona) proved that a sprayable dsRNA insecticide can be registered in the US — but no public source reviewed shows RNAissance itself having filed for or obtained a registration, closed a priced institutional round, or announced a commercial partnership since 2022. The absence of public newsflow from 2023 through October 2026 is itself an important finding.

RevenueN/A
Employees14
Market CapN/A
Founded2019
Missouri, US
Riken

Riken Vitamin Co., Ltd.

Premium
Information Technology

| Item | Detail | Source | |---|---|---| | Legal name | 理研ビタミン株式会社 / RIKEN VITAMIN CO., LTD. | YUHO-FY26 cover | | Former names | Riken Vitamin Oil Co., Ltd. (理研ビタミン油株式会社), from 1949 to January 1980 | YUHO-FY26 history | | Corporate lineage | Traces to RIKEN (the Institute of Physical and Chemical Research, founded 1917) via predecessor Riken Eiyo Yakuhin (1938). The vitamin division personnel spun out in 1949. | YUHO-FY26 | | Founding / incorporation | 27 August 1949, with capital of ¥3 million | YUHO-FY26; company IR deck Jan 2023 | | Incorporation jurisdiction | Japan (Companies Act) | YUHO-FY26 | | Corporate structure | Company with an Audit & Supervisory Committee (監査等委員会設置会社), adopted June 2017 | YUHO-FY26 | | Headquarters | 1-6-1 Yotsuya, Shinjuku-ku, Tokyo, Japan. Relocated from Chiyoda-ku in November 2020. | YUHO-FY26 | | Exchange / ticker | Tokyo Stock Exchange Prime Market: 4526. Listed October 1961 (2nd Section), moved to 1st Section December 2014, Prime from April 2022. | YUHO-FY26 | | ISIN / CUSIP | confirm via JPX. CUSIP not applicable (no US listing or ADR identified). | — | | Fiscal year end | 31 March | TANSHIN-FY26 | | Share capital | ¥2,537 million | YUHO-FY26 | | Shares issued | 30,705,100 at 31 Mar 2026. Treasury shares were 1,517,289, including 187,988 held in BIP/ESOP trusts. | TANSHIN-FY26 | | Employees (consolidated) | 1,887 at 31 Mar 2026, plus 453 average temporary staff | YUHO-FY26 | | Employees (parent) | 1,016; average age 39.5; average tenure 15.5 years; average salary ¥8.41 million | YUHO-FY26 | | Auditor | KPMG AZSA LLC (有限責任 あずさ監査法人), 20 consecutive years. Audit fee FY2026: ¥122 million. | YUHO-FY26 | | Market capitalisation | ≈¥102.1 billion on issued-share basis at ¥3,325 (28 Sep 2026, kabuyoho). ≈¥95 billion excluding treasury shares (analyst estimate). | kabuyoho; analyst calc | | Group composition | Parent plus 18 subsidiaries: 14 consolidated (4 domestic, 10 overseas) and 4 non-consolidated | YUHO-FY26 | | Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---|---| | Employees consolidated (persons) | 1825 | 1848 | 1857 | 1858 | 1887 | | Employees parent (persons) | 958 | 957 | 966 | 997 | 1016 | | Temporary staff consolidated avg (persons) | 419 | 430 | 438 | 451 | 453 | Source: YUHO-FY26, five-year summary. Riken Vitamin is a mid-cap Japanese ingredients-and-foods maker whose identity comes from RIKEN's natural vitamin-A extraction work. Its core competence is extracting, purifying, concentrating and molecularly distilling natural raw materials, especially vegetable oils, seaweed, fish and plant pigments. Consumers know it for "Fueru Wakame-chan" dried wakame, wakame soup and "Riken Non-Oil" dressings. Yet most sales and profit come from business-to-business products: - food-improving agents (emulsifiers such as distilled monoglycerides); - natural vitamin E antioxidants; - natural colours; - functional health ingredients; - seasonings and extracts; - polymer additives (anti-fog, anti-static, lubricant and plasticiser agents). Overseas sales are about a quarter of the group, anchored by a core emulsifier plant in Malaysia. Management targets 35% overseas sales and ¥13.5 billion operating profit by the year ending March 2035. The equity story combines three things: a cash-rich, low-leverage balance sheet; rising shareholder returns (a payout floor of 40% or more plus buybacks); and an ongoing unwinding of cross-shareholdings. It is constrained by low expected growth, which leaves the stock at about 1x P/B. --- ### Company's own description The annual report frames the group around the founding policy of "effective utilisation of natural resources" (天然物の有効利用). It describes a group that uses proprietary technology and development capability to create products in foods, food-improving agents, chemical-improving agents and vitamins, and supplies them in Japan and worldwide. The stated management philosophy has five pillars: 1. Contributing to healthy, rich diets through food. 2. Compliance-based business conduct. 3. A flexible, creative manufacturer that uses its own "production seeds" (raw materials, technologies and equipment). 4. Building a "Riken Vitamin of the world" brand overseas. 5. A respectful, attractive workplace. Source: YUHO-FY26, section 1. The long-term vision is "to become a company that grows by supporting a sustainable society with specialty products and services" (持続可能な社会をスペシャリティな製品とサービスで支え、成長する会社になる). The goal year was moved from the company's FY2030 to its FY2034 in May 2025. Source: MTP2027. ### Reporting structure versus product structure Riken Vitamin reports three geographically defined segments: **Domestic Food Business:** household foods, commercial foods, and processed-food ingredients including food-improving agents and vitamins. **Domestic Chemical & Other Business:** chemical-improving agents and feed additives or feed oils. **Overseas Business:** food-improving agents, chemical-improving agents, extracts and seasonings. Internally, and in investor presentations, management also describes the business by product field: **Foods:** extracts and seasonings, seaweed. **Improving agents:** emulsifiers, antioxidant-grade vitamins, colours. **Healthcare:** nutritional-fortification vitamins, functional food ingredients, microcapsules. **Other:** All vitamins are booked to Healthcare, because sales cannot be split by end use. Source: company IR deck, 9 Jan 2026. ### Business model and revenue model | Engine | Customers | Economics | Indicative scale (FY2026) | |---|---|---|---| | Branded consumer foods (household) | Supermarkets, drugstores and e-commerce, via wholesalers | Brand-driven; high promotion and advertising intensity; volume-sensitive to price increases | ¥13,650 million (13.9% of gross segment sales) | | B2B foods and food solutions (commercial plus processed-food ingredients) | Processed-food manufacturers, convenience-store vendors, foodservice, school and industrial catering, bakeries, noodle makers | Specification-driven; application centres support co-development; price revisions lag input costs | ¥52,710 million (53.8%) | | Industrial / chemical additives and overseas ingredients | Plastics converters, packaging-film makers, agricultural-film makers, rubber, cosmetics, feed; global food manufacturers | Commodity-plus-specialty mix; exposed to palm and vegetable-oil pricing and to competition from Western and Chinese emulsifier makers | ¥31,579 million (Domestic Chemical plus Overseas, gross) | Riken Vitamin is a manufacturer whose revenue is almost entirely product sales recognised at a point in time. The annual report confirms that all FY2025 and FY2026 revenue is "goods transferred at a point in time", with no over-time revenue. There is no material subscription, licensing or service revenue. Revenue is reduced by rebates and promotional allowances to distributors and retailers. These rebates are a critical accounting estimate: accrued promotion expenses were ¥636 million at FY2026 year-end. Source: YUHO-FY26 and TANSHIN-FY26 notes. The model has three distinct economic engines: Source: TANSHIN-FY26 segment breakdown; analyst grouping. ### Value-chain position Riken Vitamin sits mid-stream. It buys imported vegetable oils and palm derivatives, mainly through trading houses and oil refiners. It buys aquacultured wakame from Sanriku (Iwate and Miyagi), gardenia fruit and other botanicals, and animal-derived raw materials such as pork for extracts made in Oklahoma. It converts these by distillation, esterification, extraction and blending into: - ingredients sold to food and chemical manufacturers; and - branded packaged foods sold through distribution. It is also vertically integrated upstream in seaweed. Through subsidiary Riken Foods it runs wakame seedling development at "Yuriage Factory" in Natori, Miyagi (opened 2017), and land-based green-laver (スジアオノリ) aquaculture at "Rikuzentakata Base" in Iwate (opened October 2021). Source: YUHO-FY26 R&D section. ### Independent characterisation Riken Vitamin is best understood as a Japanese specialty lipid-chemistry and natural-extract company that happens to own a strong consumer brand franchise. The consumer image of "dressings and wakame" understates the B2B core, a point made explicitly by outside director Shinichi Hirano in the 2023 integrated report. Key characteristics: - Profitability is moderate (operating margin 7–10% over FY2022–FY2026). It is constrained by domestic demographic decline, input-cost volatility and commoditisation of emulsifiers overseas. - The balance sheet is a defining feature: an equity ratio of about 72%, net cash, and ¥15 billion of investment securities. - The investment case therefore depends heavily on capital allocation (buybacks, cross-shareholding unwind, payout) as much as on operations. - The 2020 Qingdao accounting scandal is a governance legacy that shaped the current subsidiary-control framework and still colours investor perception.

Revenue$0.6B
Employees1,887
Market CapN/A
Founded1949
Tokyo, Japan
Rigolleau

Rigolleau S.A.

Premium
Information Technology

Rigolleau is Argentina's oldest and largest integrated glass manufacturer. It is a 144-year-old industrial franchise operating a furnace-based plant in Berazategui (Greater Buenos Aires), plus a San Juan facility in the Chimbas/Santa Lucía area linked to its pharmaceutical ampoule business. The company sells across three business units: Hogar (household tableware and ovenware under the Rigolleau and Durax brands), Envases (glass containers for food, beverages, cosmetics and perfumery), and Pharma (pharmaceutical packaging). It is family-controlled through Industrias Integrales del Vidrio (73.96%), which is historically linked to the Cattorini family. Since 2024 the business has been caught between a sharp contraction in Argentine mass consumption, trade liberalisation that let low-cost Chinese tableware in, and energy-intensive fixed costs. Management responded by shutting furnace capacity and moving Hogar from manufacturing towards importing. It now describes its stance as one of mild optimism after H1 FY2026 volumes recovered. The equity is a micro-cap trading well below book value, and the auditors' committee has raised going-concern considerations. --- **What the company does.** Rigolleau melts silica sand, soda ash, limestone and cullet in continuously operating natural-gas-fired furnaces. It forms the melt into hollow glass: containers, tumblers, stemware, plates, bowls, jugs and heat-resistant ovenware. It sells three ways: 1. Branded finished goods to retailers, wholesalers and e-commerce resellers (Hogar). 2. Made-to-order packaging to food, beverage, cosmetics and perfumery brand owners (Envases). 3. Pharmaceutical primary packaging (Pharma). Historically this included ampoules and vials converted from neutral glass tubing at subsidiary Amposan S.A. [S15][S17]. Data-provider profiles also describe a "Promotional Glassware" line: glass articles decorated with customers' brands, such as beer and soft-drink promotional glasses [S15]. **Company's own description.** In its CNV filings the company presents itself as one of Latin America's largest producers in its category, offering integrated solutions through its Hogar, Envases and Pharma businesses [S3]. In its FY2025 Memoria the board acknowledged that the company must change its traditional business model [S2]. In practice this means supplementing local production with imported finished tableware and imported inputs and spare parts [S2][S10]. **Business and revenue model.** **Value chain position.** Rigolleau is a mid-stream converter. Upstream it depends on raw materials (silica sand, soda ash, cullet), natural gas, refractories and moulds. It has increasingly replaced domestic suppliers of inputs and spare parts with imports [S2]. Downstream, Envases sells B2B to fillers and brand owners (food, beverages, cosmetics, pharma). Hogar sells B2B2C through supermarkets, wholesalers and retail, and its products are widely resold on marketplaces such as Mercado Libre. **Customer types and end-markets.** **Independent characterisation.** Rigolleau is a high-operating-leverage, commodity-adjacent industrial whose earnings depend on furnace utilisation. Utilisation fell to roughly 60% in 2025 [S2][S3]. The packaging franchise benefits from incumbency and transport-cost protection, since glass is heavy and costly to ship. The household franchise, protected for decades by Argentine trade barriers, has lost that protection and is being restructured into an import-and-distribute brand model. The equity story is now a restructuring/recovery story, not a growth story.

RevenueN/A
Employees862
Market Cap$0.0B
Founded1882
Buenos Aires Province, Argentina
Redox

Redox Industries Ltd.

Premium
Information Technology

Redox Industries Limited is a small, founder-controlled, Ahmedabad-based agri-inputs manufacturer and trader. It has operated since 2008 in the fragmented Indian market for plant growth regulators (PGRs), biostimulants, flowering stimulants, botanical and "bio" pest-control formulations, organic and bio-fertilisers, liquid micronutrient and NPK suspensions, and technical-grade PGR actives. It sells under its own "Redox" brand and a family of "Re-"-prefixed trade names (Reset, Retry, Refund, Regold, Rowdy, Reshot Super, Refil++, Recure, Recepton). Distribution is primarily through resellers and dealers in Gujarat, and the company says it exports to South and Southeast Asia, the Gulf and Africa. It also imports and resells inputs such as humic acid, seaweed extract, amino acids, fulvic acid and sulphur. On paid-up capital, headcount and banking-limit evidence it is a micro-to-small enterprise, roughly two to four orders of magnitude smaller than India's listed crop-protection majors. Its core economic exposure is to the biostimulant category, which India's 2025 regulatory reset has fundamentally reshaped. --- ### The company's own description On its website, the company describes itself as having been founded in 2008 as a manufacturer of plant growth promoters, biostimulants, flowering stimulants, insecticides, plant nutrients and pesticides. It names Recepton/Receptone (biostimulant), Refund, Retry (growth promoter), Reset, Rowdy, Regold, Reshot Super, RDX Bio Pesticide, Sodium Ortho Nitrophenolate, Refil++ and Recure Bio Fungicide as representative products (redoxagro.com, Company Profile, accessed Oct 2026). Its IndiaMART profile adds that the product range is built on plant-based alkaloids combined with microbial enzymes. The same profile states that the company deals in its own "Redox" brand and exports to Cambodia, Dubai, Sri Lanka, Bangladesh, Vietnam and South Africa. The company also states that it imports humic acid, amino acid, seaweed extract and fulvic acid, and the home page adds sulphur and bio-pesticides to the imported list. Its stated vision is to become a leading, field-oriented and "knowledge intensive" manufacturer of technical-grade pesticides, PGRs and formulations. No annual report narrative is publicly available. ### Independent characterisation On the available evidence, Redox Industries operates a hybrid formulator-plus-trader model. It is not a molecule discoverer or a backward-integrated technical manufacturer: **Formulation and repacking:** The company reports three production lines and about INR 1 crore of investment in manufacturing equipment (website "Key Facts", self-reported, undated). Its products include liquid suspensions (zinc oxide SC 39.5% Zn, NK 6:0:18 with Ca/Mg/B, NPK 11:11:8 with Zn/B plus seaweed, boron ethanolamine 10%, ortho-silicic acid 2.0% WSL), granules (humic amino "shiny balls", bio-organic zyme granules, soil-conditioner granules), flakes (potassium humate, seaweed) and powders. These are typical blending, dissolution, granulation and packing operations, not chemical synthesis. **Trading of technical-grade and specialty actives:** The catalogue lists technical PGR and biochemical actives sold to other formulators: sodium nitrophenolate, indole-3-acetic acid, indole butyric acid, 6-benzylaminopurine, DA-6, natural brassinolide, NATCA, triacontanol 25% technical, folic, fulvic and ascorbic acids, bronopol, xanthan gum, isopropyl alcohol, emulsifier for nitrobenzene, and a "GBC/Bitrol" powder. This is a B2B input business serving the long tail of Indian agri-formulators. **Branded farm-input sales through resellers:** The website states that bulk orders are accepted only from resellers. This points to a dealer and distributor channel rather than direct-to-farmer retail. **OEM / private-label:** The website "Key Facts" table indicates that OEM service is provided, and IndiaMART notes customised packaging. **Revenue model mix (independent assessment).** Revenue is almost entirely product sales. There is no evidence of subscription, licensing or service revenue beyond bundled "technical support". The split between own-brand formulations, traded technicals and OEM work is not publicly disclosed. **Value-chain position.** The company sits mid-stream. It buys raw materials and actives (domestic and imported humates, seaweed and amino acids; PGR technicals), then formulates and packs them. It sells to (a) dealers and resellers who serve farmers and (b) other formulators who buy technicals and intermediates. **Customer types.** Agri-input dealers and distributors, other formulators and brand owners (for technicals and OEM), and overseas importers. Farmers are reached indirectly. **End-markets.** Indian horticulture and field crops (flowering and fruit-set stimulants, growth promoters, micronutrients, sucking-pest and larval control). The company's own text is concentrated on Gujarat. Its website also claims that its biotechnology products can be used as solvents in paints, fuels and lubricant additives. This claim is not substantiated and appears to be marketing copy.

RevenueN/A
Employees35
Market CapN/A
Founded2008
Ahmedabad, India
R1RCM

R1 RCM Inc

Premium
Information Technology

R1 RCM is the largest independent, end-to-end revenue cycle management ("RCM") provider serving U.S. healthcare providers, and since November 2024 it has been a private, sponsor-controlled platform executing an aggressive AI-first replatforming of its service model. Company disclosure in the FY2023 Form 10-K put headcount at approximately 30,000 as of 31 December 2023, split roughly 11,800 full-time and 500 part-time in the United States and approximately 17,600 internationally. Third-party estimates diverge materially thereafter: Revelio Labs put global headcount at approximately 30,164 as of March 2026, down 1.8% year over year, with India at roughly 64.5% of the workforce, the United States at 29.6% and the Philippines at 4.2%. R1's own R37 microsite and a March 2026 company article reference "more than 34,000 RCM experts and global employees," and PitchBook lists 34,000. Indian entity filings (R1 RCM Global Private Limited) recorded 16,445 employees as of 31 May 2024; a June 2026 CSR release cited "over 17,000 employees across Delhi NCR, Hyderabad, Bangalore and Chennai." The 30,000 versus 34,000 gap likely reflects the inclusion or exclusion of contractors and recently acquired teams; the discrepancy is unresolved in public sources. R1 is the scale incumbent in U.S. provider revenue cycle management and, since its 2024 leveraged take-private, the industry's most aggressive bet that the revenue cycle can be re-founded as a software platform rather than an offshore labour arbitrage. It serves over 3,700 hospitals, 93–95 of the top 100 U.S. health systems and more than 30,000 physicians, and touches over $1 trillion of net patient revenue. Its economic model is unusual: multi-year, risk-bearing operating partnerships in which R1 absorbs a customer's revenue cycle cost base and earns a negotiated cost-to-collect plus performance incentives, layered with higher-margin modular products sold into a vast installed base. The strategic wager under TowerBrook and CD&R is the Phare Operating System — an agentic AI platform launched in October 2025 — which is intended to break the historical linkage between revenue growth and headcount growth, and thereby re-rate a services multiple toward a software one. --- ### What the company actually does The revenue cycle is the sequence of administrative and financial processes that begins when a patient schedules or presents for care and ends when the provider has collected every dollar owed from payers and from the patient. It encompasses scheduling, pre-registration, insurance eligibility and benefits verification, prior authorisation, financial clearance and counselling, charge capture, clinical documentation improvement, medical coding, claim submission, denial management and appeals, underpayment recovery, patient billing and collections, cash posting, reconciliation and reporting. R1 does not sell a single product into that process. It sells operational accountability for some or all of it. In its own words from the FY2023 Form 10-K, R1 describes itself as a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals and physician groups, with scalable operating models that complement a healthcare organisation's existing infrastructure and drive sustainable improvements in net patient revenue and cash flow while reducing operating cost. **Independent characterisation.** R1 is best understood as a hybrid of three businesses that most analysts persist in mis-classifying as one: 1. **A risk-bearing business process outsourcer.** Under the "operating partner" model, R1 hires the customer's revenue cycle staff, assumes the customer's third-party vendor contracts, and takes over the function. R1 books the gross cost of running that function as cost of services and books a negotiated fee as revenue. This inflates reported revenue and structurally depresses gross margin — R1's gross margin has run in a 17–22% band, which is not a software margin and was never meant to be. This is the dominant model: the FY2023 Form 10-K states that for FY2021, FY2022 and FY2023, substantially all net operating and incentive fees from end-to-end RCM services were generated under the operating partner model. 2. **A contingency-fee revenue recovery business.** Acquired principally through Cloudmed (2022) and Acclara (2024), this is the "modular" side: underpayment recovery, DRG validation, government reimbursement optimisation, clinical documentation integrity, and extended business office services. These are sold on contingency or transaction-volume fees, carry materially higher incremental margins, and are sold behind whatever RCM operation the customer already runs — including a competitor's. 3. **An emerging enterprise software platform.** Phare OS, launched October 2025 and materially expanded through 2026, is the attempt to convert the first two businesses into a licensable, agentic system of intelligence. ### Revenue model and contract economics R1 disaggregates revenue into three lines: **Net operating fees:** gross base fees charged to end-to-end customers for operating their revenue cycle processes, less the corresponding costs of the customer's revenue cycle operations that R1 undertakes to pay under the RCM agreement (salaries and benefits of transitioned personnel, third-party vendor costs), less any shared cost savings. Recognised ratably as the performance obligation is satisfied; base fees are typically billed in advance of the quarter and paid monthly. Crucially, base fees lag cash collections, which is why customer cash-flow disruptions (the 2024 Ascension ransomware event being the canonical case) push R1 revenue into later periods rather than destroying it. **Incentive fees:** performance-based fees tied to agreed improvements in customer financial or operating metrics, generally measured against a defined prior-period baseline. These are the most volatile line and the first to be impaired by outages, payer behaviour shifts, or customer instability. **Modular and other:** fees from modular solutions, generally contingency-based where R1 is optimising revenue or reducing cost, and fixed-fee (correlated to a transaction volume metric) where R1 is supplying outsourced resources. **Contract duration.** End-to-end agreements typically run seven to ten years, subject to termination rights. Modular agreements typically have initial terms of up to three years. Sales cycles run six to eighteen months (or longer) for operating partnerships and two to six months for modular. **Recurring revenue.** In its January 2022 investor materials R1 characterised recurring revenue as greater than 90% of the total. ### Value chain position, customers and end markets | Metric | FY2021 | FY2022 | FY2023 | |---|---|---|---| | Ascension-affiliated revenue as % of total net services revenue | 61 | 49 | 40 | R1 sits between the provider and the payer, and increasingly attempts to sit *inside* the payer–provider interface. It is not a payer, not a clearinghouse in the classical Change Healthcare/Waystar sense, and not an EMR. It plugs into the provider's existing systems — the FY2023 Form 10-K states R1 has developed configurable interfaces and integrations with every major EMR, payer, clearinghouse and bank, and does not require changes to the customer's core patient care or financial systems. Customer types: health systems and hospitals (acute), physician groups and specialty practices (ambulatory), and post-acute settings. End markets served are exclusively U.S. healthcare provider reimbursement across fee-for-service, patient self-pay, and value-based payment models. **Customer concentration.** Hospital systems affiliated with Ascension have been R1's largest customer group in every year since formation. Net services revenue from Ascension-affiliated providers as a percentage of total: The trend line is the single most important structural fact about R1's business over the last five years: the company has been systematically de-risking a customer concentration that was once existential. Post-FY2023 concentration is not publicly disclosed, but the Acclara/Providence transaction, the Sutter Health partnership and modular growth will have continued to dilute it. ### Scale metrics (as last disclosed) | Metric | Value | As of / source | |---|---|---| | Hospitals served | Over 3,700 | 31 Dec 2023, FY2023 Form 10-K | | Top-100 U.S. health systems served | 93 (FY2023 10-K); 94 (March 2025, R37 launch); 95 (2026, R37 microsite and LeadIQ profile) | Various | | Physicians served | Over 30,000 | 31 Dec 2023, FY2023 Form 10-K | | Net patient revenue under coverage | More than $1 trillion | 31 Dec 2023, FY2023 Form 10-K | | Patient encounters processed annually | Over 550 million | FY2023 Form 10-K | | Annual payer transactions | Over 180 million | March 2025, R37 launch release | | Proprietary payment algorithms / rules | Over 20,000 | FY2023 Form 10-K; reiterated 2025–26 | | Annual workflow actions | 1.2 billion | March 2025, R37 launch release | | Tasks automated annually | Over 200 million, equivalent to more than 5,000 FTEs of capacity | 31 Dec 2023, FY2023 Form 10-K | | Prior authorisation orders processed annually | Approximately 39 million | January 2026, R1 Prior Authorization launch | | Payer relationships | Over 95% of U.S. health insurance companies | FY2023 Form 10-K | | Net patient revenue live on Phare OS | More than $76 billion | 18 June 2026, Phare Intelligence release |

RevenueN/A
Employees30,200
Market CapN/A
Founded2003
Utah, US

Page 94 of 482

1…939495…482

Page 94 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo